WO1991018904A1 - Substituted arylsulfonamides and benzamides - Google Patents

Substituted arylsulfonamides and benzamides Download PDF

Info

Publication number
WO1991018904A1
WO1991018904A1 PCT/US1991/003793 US9103793W WO9118904A1 WO 1991018904 A1 WO1991018904 A1 WO 1991018904A1 US 9103793 W US9103793 W US 9103793W WO 9118904 A1 WO9118904 A1 WO 9118904A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
amino
ethyl
pharmaceutically acceptable
methylsulfonyl
Prior art date
Application number
PCT/US1991/003793
Other languages
French (fr)
Inventor
John W. Ellingboe
Jehan Framoz Bagli
Michael W. Winkley
Original Assignee
American Home Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corporation filed Critical American Home Products Corporation
Priority to JP91510857A priority Critical patent/JPH05507702A/en
Publication of WO1991018904A1 publication Critical patent/WO1991018904A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • Class III antiarrhythmic agents may be categorized as having the ability to markedly prolong cardiac action potential duration without producing significant changes in maximal upstroke velocity. Unlike Class I antiarrhythmic agents, a pure Class III agent displays no effect on cardiac sodium channels. The electrophysiologic properties of a compound defining a Class III activity profile are observed in vivo as negligible effects on atrial, ventricular and H-V conduction times while producing a marked increase
  • Class I agents will demonstrate a marked slowing of ventricular conduction velocity, often without significant changes in the refractory period. Recent reviews of these agents are: Bexton et al.; Pharmac. Ther. 17, 315-55 (1982); Vaughan-Williams, J. Clin.
  • Winkley et al. disclosed N-[4-[(2,3,5,6-tetrahydro-[1,3,6]triazocino[1,2- a]benzimidazol-4-(1H)-yl)sulfonyl]phenyl]methanesulfonamide as a potential Class III antiarrhythmic agent in US Patent 4,882,323, November 21, 1989.
  • the compounds of the present invention differ from those disclosed by Buzby et al. and Davey et al. by the presence of a nitrogen containing heterocycle (R 4 in general formula (I) below). They differ from the compounds disclosed by Winkley et al. in that they lack a triazocino group.
  • This invention relates to substituted arylsulfonamides and benzamides of the general formula (I):
  • R 1 is H, NHSO 2 CH 3 , NO 2 , or 1-imidazolyl
  • Y is SO 2 or C(O)
  • n is 2 or 3
  • R 2 and R 3 are lower alkyl containing 1 to 6 carbon atoms or, when n is 2, R 2 and R 3 are joined to form piperazine
  • R 4 is selected from the group consisting of:
  • R 3 and R 5 are lower alkyl containing 1 to 6 carbon atoms and Z is H or
  • a preferred aspect of the present invention is the compounds of formula (I) wherein R 1 is H or NHSO 2 CH 3 ; Y is SO 2 or C(O); n is 2 or 3; R 2 and R 3 are lower alkyl containing 1 to 6 carbon atoms or, when n is 2, R 2 and R 3 are joined to form
  • R 4 is selected from the group consisting of:
  • R 3 and R 5 are lower alkyl containing 1 to 6 carbon atoms and Z is H or NHSO 2 CH 3 ; or R 3 and R 4 are joined to form
  • Z is H or NHSO 2 CH 3 and the pharmaceutically accepted salts thereof.
  • a further preferred aspect of the present invention are the compounds: N-methyl-N-[2-[methyl(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]-4- [(methylsulfonyl)amino]benzenesulfonamide;
  • the pharmaceutically acceptable salts of the antiarrhythmic agents of this invention are prepared directly by neutralization of the free base.
  • physiologically acceptable salts may be formed with organic or inorganic acids, such as hydrochloric, hydrobromic, phosphoric, sulfuric, sulfamic, nitric, methylsulfonic, acetic, maleic, succinic, fumaric, tartaric, citric, salicylic, lactic, napthalenesulfonic acid and the like.
  • All of the benzenesulfonamides (I)a are prepared from the amines 2 by treatment with an arylsulfonyl chloride 3 in the presence of an amine base such as triethylamine or pyridine, in an inert organic solvent such as dichloromethane, chloroform, or tetrahydrofuran at ambient temperatures.
  • an amine base such as triethylamine or pyridine
  • an inert organic solvent such as dichloromethane, chloroform, or tetrahydrofuran at ambient temperatures.
  • the benzamides (I)b (Scheme lb) are prepared from the amines 2 by treatment with a benzoic acid 4 in the presence of amide coupling reagents such as dicyclohexylcarbodiimide (DCC) and 1-hydroxybenztriazole (HOBT), in an inert organic solvent or combination of solvents such as tetrahydrofuran and dimethylformamide at ambient temperatures.
  • amide coupling reagents such as dicyclohexylcarbodiimide (DCC) and 1-hydroxybenztriazole (HOBT)
  • DCC dicyclohexylcarbodiimide
  • HOBT 1-hydroxybenztriazole
  • the benzamides (I)b can also be prepared by treatment of the amines 2 with a benzoyl chloride 5 in the presence of an amine base such as triethylamine or pyridine, in an inert organic solvent such as dichloromethane, chloroform, or tetrahydrofuran, at low (-23°C to 5°C) to ambient temperatures.
  • a benzoyl chloride 5 in the presence of an amine base such as triethylamine or pyridine, in an inert organic solvent such as dichloromethane, chloroform, or tetrahydrofuran, at low (-23°C to 5°C) to ambient temperatures.
  • the intermediate amines 2 are prepared from a substituted heterocycle 6 by treatment with a diamine 7 in the presence of an amine base such as triethylamine or an inorganic base such as sodium or potassium carbonate with or without an alcoholic solvent such as ethanol, 1-butanol, or 3-methyl-1-butanol, at temperatures ranging from ambient to reflux.
  • an amine base such as triethylamine or an inorganic base such as sodium or potassium carbonate
  • an alcoholic solvent such as ethanol, 1-butanol, or 3-methyl-1-butanol
  • the intermediate amine 2b (Scheme lIb) is prepared from 2-chloronitrobenzene 8 by treatment with ethanolamine in an alcoholic solvent such as ethanol, 1-butanol, or 3-methyl-1-butanol at temperatures from ambient to reflux; reduction of the nitro group in compound 9 with tin(II) chloride in ethanol at temperatures from ambient to reflux; conversion of the diaminobenzene 10 to the benzimidazole 11 by treatment with methyl isocyanate and iodomethane in an alcoholic solvent such as methanol, ethanol, or 1- butanol at temperatures ranging from ambient to reflux; and conversion of the hydroxy group in 11 to a methylamino group by formation of a mesylate with methanesulfonyl chloride, in the presence of an amine base such as triethylamine or pyridine, in an inert organic solvent such as dichloromethane, chloroform, or tetrahydrofuran, at low (-
  • the intermediate amine 2c is prepared from 2-chlorobenzimidazole 12 by treatment with diethanolamine in an alcoholic solvent such as 1-butanol or 3-methyl-1-butanol at temperatures ranging from ambient to reflux to yield the substituted benzimidazole 13; cyclization to the imidazo[1,2-a]benzimidazole 14 by treatment with thionyl chloride and dimethylformamide at temperatures ranging from ambient to reflux; and conversion of the chloro group to a methylamino group by the following sequence: replacement of the chloride by an iodide by treatment with sodium iodide in a ketone solvent such as acetone or 2-butanone at temperatures ranging from ambient to reflux, and treatment with methylamine in water or an alcoholic solvent at ambient temperature.
  • an alcoholic solvent such as 1-butanol or 3-methyl-1-butanol
  • the compounds of this invention display a Class III antiarrhythmic profile.
  • the class III antiarrhythmic activity was established in vitro and in vivo in accordance with the following standard test procedures:
  • Bundles of free-running Purkinje fibers with attached myocardium obtained from either ventricle of adult dog heart were pinned without stretching to the bottom of a 10 mL tissue chamber and continuously superfused with oxygenated Tyrode's solution at a flow rate of 5 mL/min.
  • the composition of the Tyrode's solution was (mM): NaCl, 138; KCl, 4; CaCl 2 , 2; MgCl 2 , 0.5; NaHCO 3 , 24; dextrose, 5.5.
  • the solution was aerated with 95% O 2 /5% CO 2 at 37°C.
  • the bath temperature was maintained at 37 ⁇ 0.5°C by circulating the prewarmed superfusate through a thermostatically controlled water bath immediately prior to entering the tissue chamber.
  • the preparations were stimulated through bipolar Teflon-coated silver wires, bared at the tips, placed on the endocardial surface of the attached myocardium, using a digital stimulator set to deliver constant current pulses 1.5 msec, in duration at cycle lengths of 300 or 1000 msec. Stimulus strength was set at approximately 2 x diastolic threshold, and adjusted as required throughout the experiment. All preparations were allowed to equilibrate in the tissue chamber for at least 1 hour before measurements were begun. Subsequently, a minimum of 60 minutes were allowed for equilibration with each drug- containing superfusate before post-drug measurements were made. Impalements were made at 6 to 10 sites throughout the preparation before and after drug exposure. Offset potentials were rechecked after each impalement.
  • V max The first derivative of the action potential upstroke (V max ) was obtained using an analog differentiator circuit, coupled to a peak-hold circuit that retained the recorded value of V max for 30 to 70 msec. Action potential and V max tracings were displayed on a storage oscilloscope, and photographed for later analysis. In addition, chart paper recordings of V max were obtained using the peak-hold device output.
  • Fresh stock solutions of drug were prepared for each experiment. Compounds were dissolved in distilled water at total concentrations of 1 to 10 mg/mL, and subsequently diluted to a final concentration of 3 to 10 ⁇ M in appropriate volumes of normal Tyrode's solution for evaluation.
  • V act diastolic take-off potential
  • V os AP overshoot
  • V max maximal upstroke velocity
  • Mongrel dogs of both sexes weighing 12 to 18 kg were anesthetized with sodium pentobarbital (35 mg/kg i.v. supplemented with 5 mg/kg/h) and artificially ventilated with room air (minute volume: 200 mL/kg).
  • the heart was exposed by a right thoracotomy performed at the fifth intercostal space and suspended in a pericardial cradle.
  • Epicardial electrodes for stimulation and recording were sutured to the free wall of the lower right atrium and near the base of the right ventricle.
  • Each electrode set contained a linear array of electrodes consisting of 1 bipolar stimulating electrode and 2 bipolar recording electrodes embedded in a rigid acrylic matrix.
  • the stimulating bipole was 7 mm from the proximal recording electrode, which in turn was 10 mm from the distal recording bipole.
  • Each electrode array was oriented to be parallel to the epicardial fiber axis.
  • Arterial blood pressure and lead ECG were displayed on a chart recorder and monitored on an oscilloscope. Conduction times and refractory periods were measured during pacing at a cycle length of 300 msec.
  • the dog heart was paced by a stimulator driving a constant current isolation unit. Electrical signals from the atrial and ventricular electrodes were displayed on a digital oscilloscope and recorded on an ink-jet recorder. The diastolic threshold was determined before and after each trial.
  • Refractory periods of the right atrium (AERP) and right ventricle (VERP) were determined by introducing an extrastimulus (S 2 ) every 8 paced beats (S 1 ). The extrastimulus was followed by a 4-second rest interval during which no pacing occurred. Both S 1 and S 2 were of identical intensity (twice threshold) and duration (2 msec). The S 1 -S 2 interval was gradually decreased in 2 msec steps until the extrastimulus failed to induce a propagated response. This S 1 -S 2 interval was considered to define the effective refractory period.
  • Atrial and ventricular conduction times were measured as the time interval between the two electrograms recorded at the proximal and distal sites of the recording electrode array.
  • the time of activation for electrograms with predominantly biphasic complexes was taken as the moment when the trace crossed the zero reference line, and for triphasic complexes, as the peak of the major deflection.
  • APD -6o action potential duration at -60 mV
  • V max action potential velocity, maximum
  • AERP effective refractory period for right atrium
  • VERP effective refractory period for right ventricle
  • ACT atrial conduction time
  • VCT ventricular conduction time
  • n number of animals
  • the compounds are established as antiarrhythmic agents useful in the treatment of cardiac arrhythmias and conditions characterized by coronary artery vasospasms.
  • the compounds may be administered orally or parenterally in suitable dosage forms compatible with the route of administration, whether oral, intraperitoneal, intramuscular, intravenous, internasal, buccal, etc.
  • the effective dose range determined in the animal test models has been established at from about 1 to about 5 milligrams per kilogram host body weight (preferably from 2 to 10 mg/kg) i.v., and from about 2 to about 10 mg/kg (preferably 5 to 20 mg/kg) p.o., to be administered in single or plural doses as needed to relieve the arrhythmic dysfunction.
  • the specific dosage regimen for a given patient will depend upon age, pathological state, severity of dysfunction, size of the patient, etc.
  • Oral administration is performed with either a liquid or solid dosage unit in any conventional form such as tablets, capsules, solutions, etc., which comprise a unit dose (e.g.
  • parenteral administration with liquid dosage forms may be via sterile solutions or suspensions in aqueous or oleaginous medium. Isotonic aqueous vehicle for injection is preferred with or without stabilizers, preservatives and emulsifiers.
  • Step 4) Preparation of N-Methyl-N-[2-[methyl(1-methyl-1H-benzimidazol-2- yl)amino]ethyl]-4-[(memylsulfonyl) amino]benzenesulfonamide Hydrochloride
  • 2-[N-methyl-N-[(2-methylamino)ethyl]amino]-1-methyl-1H- benzimidazole (5.4g, 0.025 mol) and Et 3 N (2.5 g, 0.025 mol) in CH 2 CI 2 (500 mL) was added 4-[(methylsulfonyl)amino]benzenesulfonyl chloride (6.7 g, 0.025 mol).
  • Step 3 Preparation of 4-[(Methylsulfonyl)amino]-N-[2-(2-pyrimidinylamino)ethyl] benzenesulfonamide
  • N-(pyrimidin-1-yl)ethylenediamine 4.70 g, 0.034 mol
  • Et 3 N 4.7 mL, 0.034 mol
  • 4-[(methylsulfonyl)amino]- benzenesulfonyl chloride 9.17 g, 0.034 mol.
  • die mixture was washed with brine, dried (MgSO 4 ), and concentrated. Trituration with hot CH 2 CI 2 (300 mL) gave 0.92g (7%) of product as a white solid m.p. 150-152°C.
  • Step 2 Preparation of N-[2-[(1H-Benzimidazol-2-ylmethyl)methylamino]ethyl]-N- methyl-4-[(methylsulfonyl)am ino]benzenesulfonamide Dinydrochloride Hydrate
  • Et 3 N (1.12 g, 11.1 mmol
  • CHCI 3 40 mL
  • 4-(methylsulfonyl)aminobenzenesulfonyl chloride (2.99 g, 11.1 mmol).
  • Step 1) Preparation of N-[2-[(Quinolin-2-yl)amino]ethyl]acetamide
  • 2-chloroquinoline (10.00g, 0.061 mol)
  • N-acetylethylenediamine (6.24g, 0.061 mol)
  • sodium carbonate (6.48g, 0.061 mol)
  • 3-methyl-l-butanol 125 mL
  • the mixture was cooled, filtered, and the filtrate was concentrated to give 16.3g (>100%) of a yellow oil.
  • Purification by flash chromatography eluent 5% MeOH/CHCI 3 ; 10% MeOH/1% Et 3 N/CHCl 3 ) gave 6.8g (49%) of a yellow oil .
  • Step 3) Preparation of N-Methyl-N-[2-[methyl(1-ethyl-1H-benzimidazol-2-yl)amino] ethyl]-4-[(memylsulfonyl)amino]benzenesulfonamide Hydrochloride
  • Et 3 N 0.90 mL, 6.46 mmol
  • 2-[N-methyl-N-[(2- meti ⁇ ylamino)ethyl]amino]-1-ethyl-1H-benzimidazole (1.50g, 6.46 mmol) in CH 2 CI 2 (160 mL) was added 4-[(methylsulfonyl)amino]benzenesulfonyl chloride (1.74g, 6.46 mmol).
  • Step 3 Preparation of 1-(2-Hydroxyethyl)-2-methylamino-1H-benzimidazole
  • 2-(2-aminoanilino)ethanol 30.4 g, 0.200 mol
  • MeOH 100 mL
  • CH 3 NCS 14.6 g, 0.200 mol
  • MeOH 60 mL
  • Step 5 Preparation of 1-[(2-Methylamino)ethyl]-2-memylamino-1H-benzimidazole
  • 2-[2-methylamino(benzimidazol-1-yl)]ethyl methanesulfonate 8.0g, 29.7 mmol
  • 33% CH 3 NH 2 /EtOH 60 mL
  • EtOH 40 mL
  • the mixture was concentrated, made basic (pH10) with 2.5 N NaOH, and extracted with EtOAc.
  • the combined extracts were dried and concentrated to give a colorless oil. Purification by flash chromatography (eluent Et 3 N/MeOH/CH 2 Cl 2 , 1:10:84) gave 4.20g (70%) of an oil.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to substituted arylsulfonamides and benzamides of formula (I), wherein R1 is H, NHSO¿2?CH3 or 1-imidazolyl; Y is SO2 or C(O); n is 2 or 3; R?2 and R3¿ are lower alkyl or, when n is 2, R?2 and R3¿ are joined to form piperazine; R4 is selected from the group consisting of (a), (b), (c), (d) and (e), wherein R?3 and R5¿ are lower alkyl and Z is H or NHSO¿2?CH3; or R?3 and R4¿ are joined to form (f), wherein Z is H or NHSO¿2?CH3 or the pharmaceutically acceptable salt thereof, possessing antiarrhythmic activity, to pharmaceutical compositions and to methods for production thereof.

Description

SUBSTITUTED ARYLSULFONAMIDES AND BENZAMIDES BACKGROUND OF THE INVENTION
Class III antiarrhythmic agents may be categorized as having the ability to markedly prolong cardiac action potential duration without producing significant changes in maximal upstroke velocity. Unlike Class I antiarrhythmic agents, a pure Class III agent displays no effect on cardiac sodium channels. The electrophysiologic properties of a compound defining a Class III activity profile are observed in vivo as negligible effects on atrial, ventricular and H-V conduction times while producing a marked increase
(greater than 20 percent) in both the atrial and ventricular refractory period. In contrast,
Class I agents will demonstrate a marked slowing of ventricular conduction velocity, often without significant changes in the refractory period. Recent reviews of these agents are: Bexton et al.; Pharmac. Ther. 17, 315-55 (1982); Vaughan-Williams, J. Clin.
Pharmacol. 24, 129-47 (1984); Steinberg et al., Ann. Rep. Med. Chem. 21, 95-108
(1986) and Colatsky and Follmer, Drug Development Research 19; 129-140 (1990).
Buzby et al. recently disclosed 4-methylsulfonamido-N-[2-[(1-methylethyl)amino]- ethyl]benzenesulfonamide as a potential Class III antiarrhythmic agent in US Patent
4,721,809, January 26, 1988.
Davey et al. disclosed N-[2-(diethylamino)ethyl-4-[(methylsulfonyl)amino]benzamide as a potential Class III antiarrhythmic agent in US Patent 4,544,654, October 1, 1985.
Winkley et al. disclosed N-[4-[(2,3,5,6-tetrahydro-[1,3,6]triazocino[1,2- a]benzimidazol-4-(1H)-yl)sulfonyl]phenyl]methanesulfonamide as a potential Class III antiarrhythmic agent in US Patent 4,882,323, November 21, 1989.
The compounds of the present invention differ from those disclosed by Buzby et al. and Davey et al. by the presence of a nitrogen containing heterocycle (R4 in general formula (I) below). They differ from the compounds disclosed by Winkley et al. in that they lack a triazocino group.
DESCRIPTION OF THE INVENTION
This invention relates to substituted arylsulfonamides and benzamides of the general formula (I):
(I)
Figure imgf000004_0003
wherein R1 is H, NHSO2CH3, NO2, or 1-imidazolyl; Y is SO2 or C(O); n is 2 or 3; R2 and R3 are lower alkyl containing 1 to 6 carbon atoms or, when n is 2, R2 and R3 are joined to form piperazine; R4 is selected from the group consisting of:
Figure imgf000004_0002
wherein R3 and R5 are lower alkyl containing 1 to 6 carbon atoms and Z is H or
NHSO2CH3; or R3 and R4 are joined to form
Figure imgf000004_0001
wherein Z is H or NHSO2CH3 and the pharmaceutically acceptable salts thereof. A preferred aspect of the present invention is the compounds of formula (I) wherein R1 is H or NHSO2CH3; Y is SO2 or C(O); n is 2 or 3; R2 and R3are lower alkyl containing 1 to 6 carbon atoms or, when n is 2, R2 and R3 are joined to form
piperazine; R4 is selected from the group consisting of:
V
Figure imgf000005_0002
wherein R3 and R5 are lower alkyl containing 1 to 6 carbon atoms and Z is H or NHSO2CH3; or R3 and R4 are joined to form
Figure imgf000005_0001
wherein Z is H or NHSO2CH3 and the pharmaceutically accepted salts thereof.
A further preferred aspect of the present invention are the compounds: N-methyl-N-[2-[methyl(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]-4- [(methylsulfonyl)amino]benzenesulfonamide;
4-[(methylsulfonyl)am ino]-N-[2-(2-pyrimidinylamino)ethyl]benzenesulfonamide;
N-methyl-N-[2-[methyl(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]-4- [(methylsulfonyl)amino]benzamide;
4-[(methylsulfonyl)a mino]-N-[2-[(quinolin-2-yl)amino]ethyl]benzenesulfonamide;
N-methyl-N-[2-[methyl(1-ethyl-1H-benzi midazol-2-yl)amino]ethyl]-4- [(methylsulfonyl)amino]benzenesulfonamide;
N -methyl-N-[2-[methyl[(1-methyl-1H-benzimidazol-2-yl)methyl]amino]ethyl]-4- [(methylsulfonyl)amino]benzamide; N-methyl-N-[2-[methyl[(1-methyl-1H-benzimidazol-2-yl)methyl]amino]ethyl]-4- [(methylsulfonyl)amino]benzenesulfonamide;
N-methyl-N-[2-[methyl(quinolin-2-yl)amino]ethyl]-4-[(methylsulfonyl)amino]- benzenesulfonamide;
N-methyl-N-[2-[methyl[5-[(methylsulfonyl)am ino]-1H-benzimidazol-2-yl]amino]- ethyl]benzamide;
N-methyl-N-[2-(2,3-dihydro-1H-imidazo[1,2-a]benzimidazol-1-yl)ethyl]-4- [(methylsulfonyl)amino]benzenesulfonamide;
N-methyl-N-[2-[methyl(quinolin-2-yl)amino]ethyl]-4- [(methylsulfonyl)amino]benzamide; N-[2-[(1H-benzimidazol-2-ylmethyl)methylamino]ethyl]-N-methyl-4- [(methylsulfonyl)a mino]benzenesulfonamide;
N-methyl-N-[3-[methyI(1-methyl-1H-benzimidazol-2-yl)amino]propyl]-4- [(methylsulfonyl)amino]benzenesulfonamide;
N-methyl-N-[2-[methyl(1H-benzimidazol-2-yl)amino]ethyl]-4-[(methylsulfonyl)amino]- benzenesulfonamide;
N-[4-(1-methyl-1H-benzimidazol-2-yl)-1-piperazinyl]-4-[(methylsulfonyl)amino]- benzamide; N-[4-[[4-(1-methyl-1H-benzimidazol-2-yl)-1-piperazinyl]sulfonyl]phenyl]- methanesulfonamide;
N-methyl-N-[2-(2-methylamino)-1H-benzimidazol-1-yl)ethyl]-4- [(methylsulfonyl)amino]benzenesulfonamide;
N-[2-[(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]-4-[(methylsulfonyl)amino]- benzenesulfonamide;
N-methyl-N-[2-[(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]-4- [(methylsulfonyl)amino]benzenesulfonamide and the pharmaceutically acceptable salts thereof.
It is to be understood that the definition of the compounds of formula (I) encompass all possible stereoisomers and mixtures thereof which possess the activity discussed below. In particular, it encompasses racemic modifications and any optical isomers which possess the indicated activity.
The pharmaceutically acceptable salts of the antiarrhythmic agents of this invention are prepared directly by neutralization of the free base. These physiologically acceptable salts may be formed with organic or inorganic acids, such as hydrochloric, hydrobromic, phosphoric, sulfuric, sulfamic, nitric, methylsulfonic, acetic, maleic, succinic, fumaric, tartaric, citric, salicylic, lactic, napthalenesulfonic acid and the like.
PROCESS
The compounds of the present invention are prepared according to the general sequences outlined in Schemes I and II below:
Scheme I: Preparation of (I)a and (I)b
a)
v
v
V
b) fΛ 4
c)
Figure imgf000008_0001
wherein R1, R2, R3, R4 and n are as defined above. (I)a designates those compounds of formula (I) wherein Y is SO2. (I)b designates those compounds of formula (I) wherein Y is C(O). Scheme II: Preparation of 2
a)
b)
c)
Figure imgf000009_0001
wherein R2, R3, R4 and Z are as defined above. PROCESS
All of the benzenesulfonamides (I)a (Scheme la) are prepared from the amines 2 by treatment with an arylsulfonyl chloride 3 in the presence of an amine base such as triethylamine or pyridine, in an inert organic solvent such as dichloromethane, chloroform, or tetrahydrofuran at ambient temperatures.
The benzamides (I)b (Scheme lb) are prepared from the amines 2 by treatment with a benzoic acid 4 in the presence of amide coupling reagents such as dicyclohexylcarbodiimide (DCC) and 1-hydroxybenztriazole (HOBT), in an inert organic solvent or combination of solvents such as tetrahydrofuran and dimethylformamide at ambient temperatures.
The benzamides (I)b (Scheme lc) can also be prepared by treatment of the amines 2 with a benzoyl chloride 5 in the presence of an amine base such as triethylamine or pyridine, in an inert organic solvent such as dichloromethane, chloroform, or tetrahydrofuran, at low (-23°C to 5°C) to ambient temperatures.
The intermediate amines 2 (Scheme IIa) are prepared from a substituted heterocycle 6 by treatment with a diamine 7 in the presence of an amine base such as triethylamine or an inorganic base such as sodium or potassium carbonate with or without an alcoholic solvent such as ethanol, 1-butanol, or 3-methyl-1-butanol, at temperatures ranging from ambient to reflux.
The intermediate amine 2b (Scheme lIb) is prepared from 2-chloronitrobenzene 8 by treatment with ethanolamine in an alcoholic solvent such as ethanol, 1-butanol, or 3-methyl-1-butanol at temperatures from ambient to reflux; reduction of the nitro group in compound 9 with tin(II) chloride in ethanol at temperatures from ambient to reflux; conversion of the diaminobenzene 10 to the benzimidazole 11 by treatment with methyl isocyanate and iodomethane in an alcoholic solvent such as methanol, ethanol, or 1- butanol at temperatures ranging from ambient to reflux; and conversion of the hydroxy group in 11 to a methylamino group by formation of a mesylate with methanesulfonyl chloride, in the presence of an amine base such as triethylamine or pyridine, in an inert organic solvent such as dichloromethane, chloroform, or tetrahydrofuran, at low (-23°C to 5°C) to ambient temperatures, and subsequent treatment with methylamine in water or an alcoholic solvent at ambient temperatures.
The intermediate amine 2c is prepared from 2-chlorobenzimidazole 12 by treatment with diethanolamine in an alcoholic solvent such as 1-butanol or 3-methyl-1-butanol at temperatures ranging from ambient to reflux to yield the substituted benzimidazole 13; cyclization to the imidazo[1,2-a]benzimidazole 14 by treatment with thionyl chloride and dimethylformamide at temperatures ranging from ambient to reflux; and conversion of the chloro group to a methylamino group by the following sequence: replacement of the chloride by an iodide by treatment with sodium iodide in a ketone solvent such as acetone or 2-butanone at temperatures ranging from ambient to reflux, and treatment with methylamine in water or an alcoholic solvent at ambient temperature.
PHARMACOLOGICAL METHODS Cardiac Electrophysiology
The compounds of this invention display a Class III antiarrhythmic profile.
The class III antiarrhythmic activity was established in vitro and in vivo in accordance with the following standard test procedures:
In Vitro
Bundles of free-running Purkinje fibers with attached myocardium obtained from either ventricle of adult dog heart were pinned without stretching to the bottom of a 10 mL tissue chamber and continuously superfused with oxygenated Tyrode's solution at a flow rate of 5 mL/min. The composition of the Tyrode's solution was (mM): NaCl, 138; KCl, 4; CaCl2, 2; MgCl2, 0.5; NaHCO3, 24; dextrose, 5.5. The solution was aerated with 95% O2/5% CO2 at 37°C. The bath temperature was maintained at 37±0.5°C by circulating the prewarmed superfusate through a thermostatically controlled water bath immediately prior to entering the tissue chamber.
The preparations were stimulated through bipolar Teflon-coated silver wires, bared at the tips, placed on the endocardial surface of the attached myocardium, using a digital stimulator set to deliver constant current pulses 1.5 msec, in duration at cycle lengths of 300 or 1000 msec. Stimulus strength was set at approximately 2 x diastolic threshold, and adjusted as required throughout the experiment. All preparations were allowed to equilibrate in the tissue chamber for at least 1 hour before measurements were begun. Subsequently, a minimum of 60 minutes were allowed for equilibration with each drug- containing superfusate before post-drug measurements were made. Impalements were made at 6 to 10 sites throughout the preparation before and after drug exposure. Offset potentials were rechecked after each impalement.
Glass microelectrodes filled with 3M KCl were coupled to high impedance negative capacitance electrometers and Ag/AgCl half-cells used as reference electrodes. The first derivative of the action potential upstroke (Vmax) was obtained using an analog differentiator circuit, coupled to a peak-hold circuit that retained the recorded value of Vmax for 30 to 70 msec. Action potential and Vmax tracings were displayed on a storage oscilloscope, and photographed for later analysis. In addition, chart paper recordings of Vmax were obtained using the peak-hold device output.
Fresh stock solutions of drug were prepared for each experiment. Compounds were dissolved in distilled water at total concentrations of 1 to 10 mg/mL, and subsequently diluted to a final concentration of 3 to 10 μM in appropriate volumes of normal Tyrode's solution for evaluation.
Action potential (AP) parameters measured included: diastolic take-off potential (or activation voltage (Vact); AP overshoot (Vos); AP duration measured as the time taken to repolarize to -20mV (APD-20), -60 mV (APD-60), and -80 mV (APD-80); and maximal upstroke velocity (Vmax). An increase in APD-60 that occurred without a significant change in Vmax was taken, by definition, to indicate Class III antiarrhythmic activity "in vitro". In Vivo
Mongrel dogs of both sexes weighing 12 to 18 kg were anesthetized with sodium pentobarbital (35 mg/kg i.v. supplemented with 5 mg/kg/h) and artificially ventilated with room air (minute volume: 200 mL/kg).
The heart was exposed by a right thoracotomy performed at the fifth intercostal space and suspended in a pericardial cradle. Epicardial electrodes for stimulation and recording were sutured to the free wall of the lower right atrium and near the base of the right ventricle. Each electrode set contained a linear array of electrodes consisting of 1 bipolar stimulating electrode and 2 bipolar recording electrodes embedded in a rigid acrylic matrix. The stimulating bipole was 7 mm from the proximal recording electrode, which in turn was 10 mm from the distal recording bipole. Each electrode array was oriented to be parallel to the epicardial fiber axis.
Arterial blood pressure and lead ECG were displayed on a chart recorder and monitored on an oscilloscope. Conduction times and refractory periods were measured during pacing at a cycle length of 300 msec. The dog heart was paced by a stimulator driving a constant current isolation unit. Electrical signals from the atrial and ventricular electrodes were displayed on a digital oscilloscope and recorded on an ink-jet recorder. The diastolic threshold was determined before and after each trial.
Refractory periods of the right atrium (AERP) and right ventricle (VERP) were determined by introducing an extrastimulus (S2) every 8 paced beats (S1). The extrastimulus was followed by a 4-second rest interval during which no pacing occurred. Both S1 and S2 were of identical intensity (twice threshold) and duration (2 msec). The S1-S2 interval was gradually decreased in 2 msec steps until the extrastimulus failed to induce a propagated response. This S1-S2 interval was considered to define the effective refractory period.
Atrial and ventricular conduction times (ACT and VCT) were measured as the time interval between the two electrograms recorded at the proximal and distal sites of the recording electrode array. The time of activation for electrograms with predominantly biphasic complexes was taken as the moment when the trace crossed the zero reference line, and for triphasic complexes, as the peak of the major deflection.
Animals received the test compound by i.v. injection. Drugs were administered cumulatively at the following dose levels: 1, 2.5, 5, 7.5, and 10 mg/kg. Each dose was administered over a 3 minute period. Electrophysiologic testing was performed 15 minutes following the end of dosing. Every 30 minutes the dog received the next incremental dose.
Vehicle-treated animals did not show any significant change of the electrophysiologic parameters. An increase in ERP that occurred without a significant decrease of CT was taken, by definition, to indicate "in vivo" Class III antiarrhythmic activity.
The results of the assays are set forth in the tables below.
Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000016_0001
1) Purkinje fiber; percent change at 3 uM, unless otherwise noted BCL: basic cycle length
APD-6o: action potential duration at -60 mV
Vmax: action potential velocity, maximum
Figure imgf000017_0001
1) Anesthetized dog model; percent change
Dose: mg/Kg i.v., unless otherwise noted AERP: effective refractory period for right atrium VERP: effective refractory period for right ventricle ACT: atrial conduction time
VCT: ventricular conduction time
HR: heart rate
BP: blood pressure
n: number of animals
i.d.: intra-duodenal administration
Based upon the activity profile elicited by the compounds of this invention in the above-described standard scientifically recognized test models, the compounds are established as antiarrhythmic agents useful in the treatment of cardiac arrhythmias and conditions characterized by coronary artery vasospasms. For that purpose, the compounds may be administered orally or parenterally in suitable dosage forms compatible with the route of administration, whether oral, intraperitoneal, intramuscular, intravenous, internasal, buccal, etc. The effective dose range determined in the animal test models has been established at from about 1 to about 5 milligrams per kilogram host body weight (preferably from 2 to 10 mg/kg) i.v., and from about 2 to about 10 mg/kg (preferably 5 to 20 mg/kg) p.o., to be administered in single or plural doses as needed to relieve the arrhythmic dysfunction. The specific dosage regimen for a given patient will depend upon age, pathological state, severity of dysfunction, size of the patient, etc. Oral administration is performed with either a liquid or solid dosage unit in any conventional form such as tablets, capsules, solutions, etc., which comprise a unit dose (e.g. from about 50 milligrams to about 400 milligrams) of the active ingredient alone or in combination with adjuvants needed for conventional coating, tableting, solubilizing, flavoring or coloring. Parenteral administration with liquid dosage forms may be via sterile solutions or suspensions in aqueous or oleaginous medium. Isotonic aqueous vehicle for injection is preferred with or without stabilizers, preservatives and emulsifiers.
The following examples illustrate the preparation of a representative number of compounds of this invention.
EXAMPLE 1
N-Methyl-N-[2-rmethyl(1-methyl-1H-benzimidazol-2-yl)a mino]ethyl]-4- [(methylsuIfonyl)amino]benzenesuIfonamide Hydrochloride
Step 1) Preparation of 2-Chlorobenzimidazole
According to the procedure D. Harrison, et al., J. Chem. Soc, 2930, 1963, a mixture of 2-hydroxybenzimidazole (40.0g, 0.298 mol) and phosphoryl chloride (400 mL) was heated under reflux for 3 hours, cooled, and concentrated. The resulting slurry was poured onto ice and the solid (starting material) was removed by filtration. The filtrate was adjusted to pH 6 with 30% aqueous NH3 and the resulting white precipitate was collected by filtration and dried to give 26.1g (57%) of product m.p. 184-186°C. NMR (DMSO-d6, 300 MHz): δ 7.21 (m, 2H), 7.50 (m, 2H).
Step 2) Preparation of 2-Chloro-1-methylbenzimidazole
According to the procedure D. Harrison, et al., J. Chem. Soc, 2930, 1963, to a cooled (5° C), stirred solution of 2-chlorobenzimidazole (26.1g, 0.171 mol) in DMF (125 mL) was added NaH (60% dispersion in mineral oil; 7.2 g, 0.180 mol) in several portions. After 30 minutes Mel (25.5g, 0.180 mol) was added. The cooling bath was removed and stirring was continued for 30 minutes. The mixture was recooled, H2O (200 mL) was added, and the resulting precipitate was collected by filtration to give 20.2g (71%) of product as an off-white solid m.p. 107-109°C.
NMR (DMSO-d6, 300 MHz): δ 3.78 (s, 3H), 7.20-7.33 (m, 2H), 7.58 (m, 2H).
Step 3) Preparation of 2-[N-Methyl-N-[(2-methylamino)ethyl]amino]-1-methyl-1H- benzimidggazole
A solution of 2-chloro-1-methylbenzimidazole (5.00g, 0.030 mol) in N,N'- dimethylethylenediamine (25 mL, 0.235 mol) was heated under reflux for 16 hours. The mixture was concentrated, dissolved in 10% aqueous HOAc (100 mL), and extracted with EtOAc. The aqueous phase was basified to pH 9 with solid KOH and extracted with EtOAc. The extracts were dried (MgSO4) and concentrated to give a yellow oil 5.39g (82%).
NMR (DMSO-d6, 300 MHz): δ 2.29 (s, 3H), 2.72 (t, J=6.7, 2H), 2.93 (s, 3H), 3.30 (t, J = 6.7, 2H), 3.62 (s, 3H), 7.04 (m, 2H), 7.28 (m, 1H), 7.34 (m, 1H). Step 4) Preparation of N-Methyl-N-[2-[methyl(1-methyl-1H-benzimidazol-2- yl)amino]ethyl]-4-[(memylsulfonyl) amino]benzenesulfonamide Hydrochloride To a stirred solution of 2-[N-methyl-N-[(2-methylamino)ethyl]amino]-1-methyl-1H- benzimidazole (5.4g, 0.025 mol) and Et3N (2.5 g, 0.025 mol) in CH2CI2 (500 mL) was added 4-[(methylsulfonyl)amino]benzenesulfonyl chloride (6.7 g, 0.025 mol). After 18 hours (1 hour sufficient), the solution was washed with brine, saturated aqueous NaHCO3, dried (MgSO4) and concentrated to about 50 mL. The resulting white crystalline solid was collected by filtration 9.0 g of product m.p.192-193°C. The free base was suspended in MeOH (40 mL) and saturated methanolic HCl (100 mL) was added. All material went into solution, then a precipitate formed which was collected by filtration to give 7.6 g of product. This material was recrystallized from EtOH/H2O (250 mL/10 mL) to give 6.1g (50%) of colorless needles m.p. 210-213°C.
NMR (DMSO-d6, 400 MHz): δ 2.67 (s, 3H), 3.12 (s, 3H), 3.29 (t, J=5.6, 2H), 3.36 (s, 3H), 3.83 (s,H), 3.87 (t, J=5.6, 2H), 7.35 (d, J=8.8, 2H), 7.50 (m, 2H), 7.64 (m, 2H), 7.71 (d, J=8.8, 2H), 10.51 (s, 1H), 13.90 (br s, 1H) IR (KBr, cm-1): 3400 (NH), 1625 (C = N)
MS (m/e): 452 (MH+)
Anal. Calcd. for C19H26CIN5O4S2: C, 46.76; H, 5.37; N, 14.35%
Found: C, 46.70; H, 5.23; N, 14.34%. EXAMPLE 2
4-[(MethylsuIfonyl)amino]-N-[2-(2- pyrimidinyla mino)ethyl]benzenesulfonamide
Step 1) Preparation of N-[2-[(Pyrimidin-1-yl)amino]ethylacetamide
A mixture of 2-chloropyrimidine (5.00g, 0.0436 mol) ), sodium carbonate (4.63g, 0.0436 mol), N-acetylethylenediamine (4.46g, 0.0436 mol), and 3-methyl-1-butanol (100 mL) was heated under reflux for 19 hours. The mixture was filtered and the filtrate was concentrated. Trituration with ether gave an off-white solid 7.1 g (90%) m.p. 102- 103°C.
NMR (DMSO-d6, 300 MHz): δ 1.78 (s, 3H), 3.18 (m, 2H), 3.29 (m, 2H), 6.55 (dd, J= 4.7, 4.7 1H); 7.09 (t, J = 6.0, 1H), 7.95 (brs, 1H), 8.25 (d, J = 4.7, 2H). Step 2) Preparation of N-(Pyrimidin-1-yl)ethylenediamine
A solution of N-[2-[(pyrimidin-1-yl)amino]ethyl]acetamide (7.1g, 0.039 mol) in 2.5 N NaOH (47 mL, 0.118 mol) was heated under reflux for 22 hours. The mixture was cooled and the pH was adjusted to 8 with 2 N HCl (38 mL). The mixture was concentrated, suspended in EtOH (100 mL) and filtered. The filtrate was concentrated to give an oily solid 4.7 g (87%).
NMR (DMSO-d6, 300 MHz): δ 2.67 (t, J = 6.3, 2H), 3.25 (dt, J = 6.0, 6.3, 2H), 6.53 (dd, J=4.7, 4.7, 1H), 7.10 (t, J = 6.0, 1H), 8.24 (d, J = 4.7, 2H).
Step 3) Preparation of 4-[(Methylsulfonyl)amino]-N-[2-(2-pyrimidinylamino)ethyl] benzenesulfonamide To a stirred solution of N-(pyrimidin-1-yl)ethylenediamine (4.70 g, 0.034 mol) and Et3N (4.7 mL, 0.034 mol) in CH2CI2 (900 mL) was added 4-[(methylsulfonyl)amino]- benzenesulfonyl chloride (9.17 g, 0.034 mol). After 1.5 hours die mixture was washed with brine, dried (MgSO4), and concentrated. Trituration with hot CH2CI2 (300 mL) gave 0.92g (7%) of product as a white solid m.p. 150-152°C.
NMR (DMSO-d6, 400 MHz): δ 2.87 (dt, J = 6.0, 6.7, 2H), 3.10 (s, 3H), 3.27 (dt, J =
6.0, 6.7, 2H), 6.55 (dd, J = 4.8, 4.8, 1H), 7.05 (t, J = 6.0, 1H), 7.30 (d, J = 8.7, 2H), 7.61 (t, J = 6.0, 1H) 7.71 (d, J = 8.7, 2H), 8.22 (d, J = 4.8, 2H), 10.34 (s, 1H) IR (KBr, cm-1): 3280 (NH), 1600 (C = N)
MS (m/e): 372 (M+)
Anal. Calcd. for C13H17N5O4S2: C, 42.04; H, 4.61; N, 18.85%
Found: C, 41.84; H, 4.44; N, 18.50%.
EXAMPLE 3
N-[2-[(1H-Benzimidazol-2-ylmethyl)methylaminolethyl]-N- methyl-4- [(methylsulfonyl)aminolbenzensulfonamide Dihydrochloride Hydrate
Step 1) Preparation of 2-[[N-Methyl-N-[(2-methylamino)ethyl]amino]methyl]-1H- benzimidazole
A mixture of 2-chloromethylbenzimidazole (4.00 g, 24 mmol), N,N'-dimethylethylene- diamine (2.11 g, 24 mmol), potassium carbonate (3.32 g, 24 mmol) and ethanol (60 mL) was stirred at room temperature for 36 hours. The mixture was concentrated, taken up in H2O and extracted with EtOAc. The combined extracts were dried and concentrated to give a brown oil. Purification by flash chromatography (eluent 5% MeOH/CH2 Cl2) gave a colorless oil 2.42 g (40%).
NMR (DMSO - d6, 300 MHz): δ 3.05 (t, J = 4.5 Hz, 2H), 3.18 (t, J = 4.5 Hz, 2H), 3.4 (s, 3H), 4.37 (s, 2H), 4.67 (s, 3H), 7.38 (dd, J = 8.7 Hz, 4.8 Hz, 1H), 7.40 (d, J = 3.3 Hz, 1H), 7.71 (dd, J = 6.4 Hz, 4.8 Hz, 1H), 7.74 (dd, J = 6.4 Hz, 3.3 Hz, 1H), 9.15 (s, 1H).
Step 2) Preparation of N-[2-[(1H-Benzimidazol-2-ylmethyl)methylamino]ethyl]-N- methyl-4-[(methylsulfonyl)am ino]benzenesulfonamide Dinydrochloride Hydrate To a stirred mixture of 2-[[N-methyl-N-[(2-methylamino)ethyl]amino]methyl]-1H- benzimidazole (2.42 g, 11.1 mmol), Et3N (1.12 g, 11.1 mmol), and CHCI3 (40 mL) was added 4-(methylsulfonyl)aminobenzenesulfonyl chloride (2.99 g, 11.1 mmol). After 2 hours, the mixture was concentrated, taken up in H2O, and extracted with EtOAc. The extracts were washed with H2O and brine, dried, and concentrated to give a yellow solid. Purification by flash chromatography (eluent 5% MeOH/CH2 Cl2) gave an off-white solid. Saturated methanolic HCl (20 mL) was added. After several minutes, the solution was concentrated and triturated with hot EtOH. The material was recrystallized from EtOH/H2O to give a white solid 2.12 g (42%) m.p. 194-196°C. NMR (DMSO-d6, 400 MHz): δ 2.70 (s, 3H), 2.86 (s, 3H), 3.14 (s, 3H), 3.37 (br s, 4H), 4.65 (s, 2H), 7.38 (dd, J=8.7 Hz, 4.0 Hz, 1H), 7.40 (d, J=3.3 Hz, 1H), 7.71 (dd, J=6.4 Hz, 4.0 Hz, 1H), 7.74 (dd, J=6.4 Hz, 3.3 Hz, 1H), 10.56 (s, 1H)
IR (KBr, cm-1): 3450, 3250 (NH)
MS (m/e): 452 (MH+)
Anal. Calcd. for C19H29CI2N5O5S2: C, 42.07; H, 5.39; N, 12.91%
Found: C, 42.00; H, 5.25; N, 12.75%. EXAMPLE 4
N-[2-[(1-Methyl-1H-benzimidazol-2-yl)aminolethyl]-4- [(methyIsulfonyl)amino]benzenesuIfonamide Hydrochloride Hemihydrate
Step 1) Preparation of N-[2-[(1-Methyl-1H-benzimidazol-2-yl)amino]ethyl]acetamide
A mixture of 2-methylsulfonyl-1-methyl-1H-benzimidazole (7.0g, 0.033 mol) and N- acetylethylenediamine (17.0g, 0.167 mol) was heated at 120-125°C for 8 hours. The mixture was cooled, diluted with H2O, made basic (pH8) with 2.5 N NaOH, and filtered. The filtrate was extracted with EtOAc, and the combined extracts were washed with brine, dried, and concentrated to give a yellow solid 2.3g (30%). NMR (DMSO-d6, 300 MHz): δ 1.82 (s, 3H), 3.32 (t, 7=6.0 Hz, 2H), 3.40 (t, J=6.0 Hz, 2H), 3.82 (s, 3H), 6.20 (m, 1H), 6.78 (m, 1H), 6.95 (m, 2H), 7.17 (d, J=6.5 Hz, 1H), 8.05 (m, 1H).
Step 2) Preparation of 2-[N-(2-Aminoethyl)amino]-1-methyl-1H-benzimidazole
A mixture of N-[2-[(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]acetamide (2.32 g, 9.98 mmol), 2N HCl (20 mL), and MeOH (20 mL) was heated under reflux for 20 hours. The mixture was concentrated, diluted with H2O, made basic (pH9) with 2.5 N NaOH, and extracted with EtOAc. The combined extracts were dried and concentrated to give a brown oil. Purification by flash chromatography (eluent 10% MeOH/CH2Cl2) gave a yellow oil 1.47 g (77%).
NMR (DMSO-d6, 300 MHz): δ 2.78 (t, J = 6.0 Hz, 2H), 3.38 (t, J = 6.0 Hz, 2H), 3.50 (s, 3H), 3.9 (brs, 2H), 6.78 (m, 1H), 6.90 (m, 2H), 7.10 (d, J = 6.5 Hz, 1H).
Step 3) Preparation of N-[2-[(1-Methyl-1H-benzimidazol-2-yl)amino]ethyl]-4-
[(methylsulfonyl)amino]benzenesulfonamide Hydrochloride Hemihydrate
To a stirred solution of 2-[N-(2-aminoethyl)amino]-1-methyl-1H-benzimidazole (1.47g, 5.59 mmol) and Et3N (0.60g, 5.59 mmol) in p-dioxane (40 mL) was added 4- [(methylsulfonyl)amino]benzenesulfonyl chloride (1.51 g, 5.59 mmol). After 2 hours, the mixture was concentrated, taken up in H2O, and extracted with EtOAc. The combined extracts were washed with H2O and brine, dried, and concentrated to give an oil. Purification by flash chromatography (eluent 5% MeOH/CH2Cl2) gave a white solid. Saturated methanolic HCl was added and the HCl salt was collected by filtration. Recrystallization from EtOH gave 0.84g (32%) of product m.p. 140-142°C. NMR (DMSO-d6, 400 MHz): δ 3.03 (m, 2H), 3.09 (s, 3H), 3.55 (m, 2H), 3.60 (s, 3H), 7.28 (m, 4H), 7.40 (m, 1H), 7.48 (m, 1H), 7.72 (m, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.88 (t, J = 6.6 Hz, 1H), 8.98 (s, 1H), 10.40 (s, 1H), 13.34 (s, 1H)
IR (KBr, cm-1): 3600 (NH)
MS (m/e): 425 (MH+)
Anal. Calcd. for C17H22CIN5O4S2• 0.5 H2O: C, 43.46; H, 4.93; N, 14.91%
Found: C, 43.84; H, 4.64; N, 14.92%.
EXAMPLE 5
N-Methyl-N-[2-[ (1-methyl-1H-henzimidazol-2- yl)a mino]ethyl]-4-[(methylsulfonyl)amino]benzenesulfonamide
Hydrochloride Hydrate
Step 1) Preparation of 2-(Methylsulfonyl)-1H-benzimidazole
According to the procedure of B. M. Trost, et al., Tetrahedron Lett. , 22 (14), 1287 (1981), to a cooled (0°C), stirred solution of 2-(methylthio)benzimidazole (14.5 g, 0.088 mol) in MeOH (350 mL) was added a solution of oxone (2 KHSO5·KHSO4·K2SO4; 81.6 g, 0.133 mol) in H2O (350 mL) over 10 minutes. The cooling bath was removed after 10 minutes, stirring was continued at room temperature for 5 hours. The MeOH was removed under reduced pressure and the white solid was collected by filtration to give 15.5 g (89%) of product m.p. 200-202°C.
NMR (DMSO - d6, 300 MHz): δ 3.50 (s, 3H), 7.40 (dd, J = 6.2 Hz, 3-1 Hz, 2H), 7.72 (brs, 2H).
Step 2) Preparation of 2-(Methylsulfonyl)-1-methyl-1H-benzimidazole
To a cooled (0°C), stirred solution of 2-(methylsulfonyl)-1H-benzimidazole (4.60 g, 0.023 mol) in DMF (25 mL) was added NaH (60% dispersion in mineral oil; 0.94 g, 0.023 mol) in several portions. After 1 hour, iodomethane (3.33 g, 0.023 mol) was added.The cooling bath was removed and stirring was continued for 18 hours. The mixture was recooled to 0° C, H2O (75 mL) was added, and the off-white precipitate was collected by filtration to give 4.30 g (88%) of product m.p. 131-132°C.
NMR (DMSO - d6, 300 MHz): δ 3.59 (s, 3H), 4.09 (s, 3H), 7.40 (m, 1H), 7.50 (m, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.82 (d, J = 8.1 Hz, 1H). Step 3) Preparation of 2-[N-[(2-Methylamino)ethyl]amino]-1-methyl-1H-benzimidazole
A mixture of 2-(methylsulfonyl)-1-methyl-1H-benzimidazole (5.0g, 0.024 mol) and N- methylethylenediamine (8.8g, 0.119 mol) was heated at 120-130°C for 12 hours. The mixture was concentrated, taken up in H2O, made basic (pH 10) with 2.5 N NaOH; and extracted with EtOAc. The combined extracts were dried and concentrated to give a brown oil. Purification by flash chromatography (eluent 10% MeOH/CH2Cl2) gave 3.0g (62%) of a yellow oil.
NMR (CDCl3, 300 MHz): δ 2.60 (s, 3H), 3.22 (t, J = 6.7 Hz, 2H), 3.52 (s, 3H), 3.81 (t, J = 6.7 Hz, 2H), 7.10 (m, 4H), 7.35 (m, 1H).
Step 4) Preparation of N-Methyl-N-[2-[(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]- 4-[(methylsulfonyl)amino]benzenesulfonamide Hydrochloride Hydrate
To a stirred solution of 2-[N-[(2-methylamino)ethyl]-1-methyl-1H-benzimidazole (3.00g, 14.7 mmol) and Et3N (1.63 g, 16.1 mmol) in p-dioxane (60 mL) was added 4- [(methylsulfonyl)aminojbenzenesulfonyl chloride (3.69g, 14.7 mmol). After 1 hour, the mixture was concentrated, taken up in H2O, and extracted with EtOAc. The extracts were washed with H2O and brine, dried, and concentrated. Purification by flash chromatography (eluent 5% MeOH/CH2Cl2) gave a white solid. Warm methanolic HCl was added and the resulting HCl salt was recrystallized from EtOH/H2O (5:1) to give 1.39g (20%) of a white solid m.p. 155-157°C.
NMR(DMSO-d6, 400 MHz): δ 2.79 (s, 3H), 3.11 (s, 3H), 3.44 (t, J = 5.8 Hz, 2H), 3.63 (s, 3H), 3.68 (m, 2H), 7.27 (m, 2H), 7.36 (m, 2H), 7.43 (dd, J = 6.4 Hz, 3.5 Hz, 1H), 7.49 (dd, J = 6.4 Hz, 3.1 Hz, 1H), 7.70 (m, 2H), 8.98 (s, 1H), 10.49 (s, 1H), 13.75 (s, 1H)
IR (KBr, cm-1): 3600 (NH)
MS (m/e): 439 (MH+)
Anal. Calcd. for C18 H24CIN5O4S2• H2O: C, 43.86; H, 5.31; N, 14.20%
Found: C, 43.92; H, 5.55; N, 14.31%. EXAMPLE 6
N-Methyl-N-[2-[methyl(1 -methyl-1H-benzimidazoI-2-yl)a mino]ethyl-4- [( methylsnlfonyl)a mino]benzamide Hydrochloride
A mixture of 2-[N-methyl-N-[(2-memylamino)ethyl]amino]-1-methyl-1H-benzimidazole (3.14g, 0.0144 mol), 4-[(methylsulfonyl)amino]benzoic acid (3.10g, 0.0144 mol), DCC (2.97g, 0.0144 mol), 1-hydroxybenztriazole hydrate (1.94g, 0.0144 mol), DMF (4 mL), and THF (42 mL) was stirred at room temperature for 2.5 days. The mixture was filtered and the filtrate was concentrated.The remaining material was taken up in CHCI3, washed with brine, saturated aqueous NaHCO3, brine, dried (MgSO4) and concentrated to give a brown oil. Purification by flash chromatography (eluent 5% MeOH/CHCl3) gave 5.00g of a white foam . Saturated methanolic HCl was added and the solution was concentrated to give a white foam. The material was stirred in boiling iPrOH (150 mL) to give a white solid 4.00g m.p. 209-212°C. Recrystallization from EtOH gave 2.20g (34%).
NMR (DMSO-d6, 400 MHz): δ 2.96 (s, 3H), 2.99 (s, 3H), 3.38 (brs, 3H), 3.79 (brs, 5H) 3.94 (brs, 2H), 7.09 (m, 4H), 7.34 (m, 2H), 7.48 (m, 1H), 7.60 (m, 1H), 10.02 (s, 1H), 13.87 (brs, 1H)
IR (KBr, cm-1): 3440 (NH), 1635 (C=O)
MS (m/e): 416 (MH+)
Anal. Calcd. for C20H26ClN5O3S: C, 53.15; H, 5.80; N, 15.49%
Found: C, 53.01; H, 5.47; N, 15.88%.
EXAMPLE 7
N-Methyl-N-[2-[ methyl(1H-benzimidazol-2- yl)aminolethyl]-4-[( methylsulfonyl)amino]benzenesulfonamide
Step 1) Preparation of 2-[N-Methyl-N-[(2-methylamino)ethyl]amino-1H-benzimidazole
A mixture of 2-chlorobenzimidazole (20.0 g, 0.131 mol), N,N'-dimethylethylenediamine (34.7 g, 0.393 mol), and EtOH (200 mL) was heated under reflux for 36 hours. The mixture was cooled, concentrated, taken up in H2O, and made basic (pH 9-10) with 2.5 N NaOH. The mixture was extracted with EtOAc, and the combined extracts were dried and concentrated to give a brown oil. Purification by flash chromatography (eluent 10% MeOH/CH2Cl2) gave 14.2g (53%) of an orange oil. NMR (DMSO-d6,300 MHz): δ 2.34 (s, 3H), 2.77 (t, J=6.5 Hz, 2H), 3.05 (t, J=6.5 Hz, 2H), 6.85 (m, 2H), 7.14 (m, 2H).
Step 2) Preparation of N-Methyl-N-[2-[methyl(1H-benzimidazol-2-yl)amino]ethyl]-4- [(methylsulfonyl)amino]benzenesulfonamide Hydrochloride
To a stirred mixture of 2-[N-methyl-N-[(2-methylamino)ethyl]amino]-1H-benzimidazole (4.00g, 19.60 mmol), Et3N (1.98g, 19.60 mmol), and p-dioxane (80 mL) was added 4- [(methylsulfonyl)amino]benzenesulfonyl chloride (5.28g, 19.60 mmol). After 1 hour, the resulting solid was collected by filtration and triturated with ether. Warm saturated methanolic HCl was added and the HCl salt was collected by filtration. Trituration with hot EtOH and recrystallization from EtOH/H2O (4:1) gave 2.78g (30%) of an off-white solid m.p. 150-152°C.
NMR (DMSO-d6, 400 MHz): δ 2.75 (s, 3H), 3.11 (s, 3H), 3.25 (t, J = 5.3 Hz, 2H), 3.27 (s, 3H), 3.83 (t, J = 5.3 Hz, 2H), 7.26 (m, 2H), 7.33 (m, 2H), 7.41 (m, 2H), 7.68 (d, J = 8.8 Hz, 2H), 10.46 (s, 1H), 13.10 (s, 1H)
IR (KBr, cm-1): 3400 (NH)
MS (m/e): 438 (4%), 360 (6%), 205 (39%), 144 (100%)
Anal. Calcd. for C18H24ClN5O4S2: C, 43.95; H, 5.33; N, 14.24%
Found: C, 44.26; H, 5.24; N, 14.29%. EXAMPLE 8
N-[2-[(Quinolin-2-yl)amino]ethyl]-4-[(methylsulfonyl)amino]- benzenesulfonamide Hydrochloride Hydrate
Step 1) Preparation of N-[2-[(Quinolin-2-yl)amino]ethyl]acetamide A mixture of 2-chloroquinoline (10.00g, 0.061 mol), N-acetylethylenediamine (6.24g, 0.061 mol), sodium carbonate (6.48g, 0.061 mol), and 3-methyl-l-butanol (125 mL) was heated under reflux for 3 days. The mixture was cooled, filtered, and the filtrate was concentrated to give 16.3g (>100%) of a yellow oil. Purification by flash chromatography (eluent 5% MeOH/CHCI3; 10% MeOH/1% Et3N/CHCl3) gave 6.8g (49%) of a yellow oil .
NMR (DMSO-d6, 300 MH): δ 1.82 (s, 3H), 3.28 (m, 2H), 3.45 (m, 2H), 6.75 (d, J = 8.6, 1H), 7.14 (m, 2H), 7.48 (m, 2H), 7.61 (d, J = 7.9, 1H), 7.84 (d,.J = 8.9, 1H), 8.02 (t, 1H).
Step 2) Preparation of N-(Quinolin-2-yl)ethylenediamine
A solution of N-[2-[(quinolin-2-yl)amino]ethyl]acetamide (6.8g, 0.030 mol) in 2N HCl (45 ml, 0.090 ml) was heated under reflux for 20 hours. The solution was cooled and extracted with EtOAc. The aqueous phase was made basic (pH9) with solid KOH, saturated with NaCl, and extracted with EtOAc. The combined extracts were dried (MgS04) and concentrated to give 3.89g (68%) of an off-white solid m.p. 124-125°C.
NMR (DMSO-d6, 300 MHz): δ 3.38 (t, J = 6.2, 2H), 3.57 (dt, J = 6.0, 6.2 2H), 6.78 (d, J = 8.8, 1H), 7.04 (t, J = 6.0, 1H), 7.10(m, 1H), 7.47 (m, 2H), 7.59 (d, J = 8.1, IH), 7.81 (d, J = 8.9, 1H).
Step 3) Preparation of N-[2-[(Quinolin-2-yl)amino]ethyl]-4-[(methylsulfonyl)amino]- benzenesulfonamide Hydrochloride Hydrate
To a stirred solution of N-(quinolin-2-yl)ethylenediamine (1.90 g, 10.15 mmol) and Et 3 N (1.14 mL, 8.18 mmol) in CH2C l 2 (200 mL) was added 4- [(methylsulfonyl)amino]benzenesulfonyl chloride (2.21g, 8.18 mmol). After 4 hours, the solution was washed with brine, dried (MgSO4), and concentrated to give a brown foam. Purification by flash chromatography (eluent 10% MeOH/CHCl3) gave 1.98g of an off-white foam. Saturated methanolic HCl (20 mL) was added and the mixture was left standing for 2 hours. The resulting colorless crystals (1.17g) were collected by filtration. Recrystallization from MeOH gave 0.72g (21%) of product m.p. 150-154°C. NMR (DMSO-d6, 400 MHz): δ 3.06 (m, 2H), 3.09 (2, 3H), 3.73 (brs, 2H), 7.11 (m, 1H) 7.31 (d, J = 8.8, 2H), 7.47 (t, J = 7.6, 1H), 7.74 (d, J = 8.8, 2H), 7.88 (d, J =7.7, 1H) 7.94 (t, J = 5.9, 1H), 8.14 (brs, 1H), 8.26 (d, J = 8.4, 1H), 9.85 (brs, 1H), 10.40 (s, 1H), 13.13 (brs, 1H)
IR (KBr, cm-1): 1660 (C = N)
MS (m/e) : 421 (MH+)
Anal. Calcd. for C18H21CIN4O4S2• H2O: C, 45.52; H, 4.88; N, 11.80%
Found: C, 45.20; H, 4.62; N, 11.55%.
EXAMPLE 9
N-Methyl-N-[2-[methyl(1-ethyl-1H-benzimidazol-2- yl)amino]ethyl]-4-[(methylsulfonyl)amino]benzenesulfonamide
Hydrochloride
Step 1) Preparation of 2-Chloro-1-ethylbenzimidazole
To a cooled (0°C) stirred suspension of NaH (60% dispersion in mineral oil; 7.08 g, 0.118 mol) in DMF (100 mL) was added 2-chlorobenzimidazole (15.00 g, 0.098 mol). The mixture was warmed to room temperature and stirred for 1 hour. Ethyl iodide (18.40 g, 0.118 mol) was added and stirring was continued for 3 hours. The mixture was poured onto the ice water and the resulting off-white solid was collected by filtration to give 10.0 g (61%) of product m.p. 48-50ºC. NMR (DMSO-d6, 300 MHz): δ 1.3 (t, J = 8.6 Hz, 3H), 4.28 (q, J = 8.6 Hz, 2H), 7.25 (m, 2H), 7.60 (m, 2H).
Step 2) Preparation of 2-[N-Methyl-N-[(2-methylamino)ethyl]amino]-1-ethyl-1H- benzimidazole
A solution of 2-chloro- 1-ethylbenzimidazole (3.1g, 0.0172 mol) in N,N'- dimethylethylendiamine (28 mL, 0.261 mol) was heated under reflux for 22 hours. The mixture was concentrated and dissolved in 10% aqueous HOAc (100 mL) and extracted with EtOAc. The aqueous phase was made basic (pH9) with solid KOH, satured with NaCl, and extracted with EtOAc. The extracts were dried (MgSO4) and concentrated to give 3.1g (78%) of a brown oil.
NMR (DMSO-d6, 300 MHz): δ 1.31 (t, J=7.2, 3H), 2.29 (s, 3H), 2.71 (t, J=6.7, 2H), 2.92 (s, 3H), 3.28 (t, J=6.7, 2H), 4.10 (q, 1=1.2, 2H), 7.05 (m, 2H),7.34 (m, 2H). Step 3) Preparation of N-Methyl-N-[2-[methyl(1-ethyl-1H-benzimidazol-2-yl)amino] ethyl]-4-[(memylsulfonyl)amino]benzenesulfonamide Hydrochloride To a stirred solution of Et3N (0.90 mL, 6.46 mmol) and 2-[N-methyl-N-[(2- metiιylamino)ethyl]amino]-1-ethyl-1H-benzimidazole (1.50g, 6.46 mmol) in CH2CI2 (160 mL) was added 4-[(methylsulfonyl)amino]benzenesulfonyl chloride (1.74g, 6.46 mmol). After 1.5 hours the solution was washed with brine, dried (MgSO4), and concentrated to give a white foam. Purification by flash chromatography (eluent 5% MeOH/CHCl3; 10% McOH/CHCl3) gave 2.31g of a white foam. Saturated methanolic HCl (23 mL) was added and the solution was concentrated to give a brown foam. Recrystallization from iPrOH, then from EtOH gave 1.05g (32%) of a white solid m.p. 185-186°C. NMR (DMSO-d6, 400 MHz): δ 1.43 (t, J = 7.2, 3H), 2.69 (s, 3H), 3.12 (s, 3H), 3.29 (t, J = 5.6, 2H), 3.36 (s, 3H), 3.84 (t, J = 5.6, 2H), 4.32 (q, J = 7.2, 2H), 7.35 (m, 4H), 7.51 (m, 1H), 7.66 (dd, J = 6.4, 2.7, 1H), 7.71 (d, J = 8.8, 2H), 10.52 (s, 1H), 13.90 (brs, 1H) IR (KBr, cm-1): 3420 (NH), 1620 (C = N)
MS (m/e): 466 (MH+)
Anal. Calcd. for C20H28CIN5O4S2: C, 47.85; H, 5.62; N, 13.95%
Found: C, 47.90; H, 5.38; N, 13.84%.
EXAMPLE 10
N-Methyl-N-[2-[methyl[(1-methyl-1H-benzim idazol-2-yl)methyl]- amino]ethyl]-4-[(methylsulfonynamino]henzamide Dihydrochloride Step 1) Preparation of 2-Chloromethyl-1-methyl-1H-benzimidazole
According to the procedure of H. Skolnik, et al., J. Chem. Soc., 65 (1943), a solution of N-methyl-o-phenylenediamine dihydrochloride (16.9g, 0.087 mol) and chloroacetic acid (12.3g, 0.130 mol) in 2N HCl (87 mL, 0.173 mol) was heated under reflux for 18 hours. The mixture was cooled, made basic (pH9) with 2.5N NaOH and the precipitate was collected by filtration. Recrystallization from ether/acetone gave 2.06g of a pale green solid m.p. 143-145°C. NMR analysis showed the material to be 2- hydroxy methyl-1-methyl-1H-benzimidazole. The filtrate from the above recrystallization was concentrated and purified by flash chromatography (eluent 5% MeOH/CHCl3 to give 5.9g (38%) of a yellow solid m.p. 95-96°C. NMR analysis showed the material to be 2-chloromethyl-1-methyl-1H-benzimidazole.
NMR (DMSO-d6, 300 MHz): δ 3.84 (s, 3H), 5.06 (s, 2H), 7.25 (m, 2H), 7.57 , (d, J = 7.3), 7.62 (d, J = 7.8, 1H). Step 2) Preparation of 2-[[N-Methyl-N-[(2-methylamino)ethyl]amino]methyl]-1- methyl-1H-benzimidazole
To a stirred solution of 2-chloromethyl-1-methyl-1H-benzimidazole (5.8g, 0.0321 mol) in EtOH (30 mL) was added N, N'-dimethylethylenediamine (14.2g, 0.161 mol). After 18 hours, the mixture was concentrated, taken up in 10% aqueous HOAc (100 mL) and extracted with ether. The aqueous phase was made basic (pH9) with solid KOH and extracted with EtOAc. The combined extracts were dried (MgSO4) and concentrated to give 5.3g (71 %) of a yellow oil. NMR (DMSO-d6, 300 MHz): δ 2.20 (s, 3H), 2.24 (s, 3H), 2.50 (m, 2H), 2.58 (m, 2H), 3.78 (s, 2H), 3.85 (s, 3H), 7.21 (m, 2H), 7.53 (d, J = 8.5, 1H), 7.60 (d, J = 7.9, 1H).
Step 3) Preparationof N-Methyl-N-[2-[methyl[(1-methyl-1H-benzimidazol-2- yl)methyl]amino]ethyl]-4-[(methylsulfonyl)amino]benzamide Dihydrochloride
A solution of 2-[[N-methyl-N-[(2-methylamino)ethyl]amino]methyl]-1-methyl-1H- benzimidazole (2.70g, 0.0116 mol), 4-[(methylsulfonyl)amino]benzoic acid (2.50g, 0.0116 mol) DCC (2.40g, 0.0116 mol), and 1-hydroxybenztriazole hydrate (1.57g, 0.0116 mol) in THF (35 mL) was stirred at room temperature for 2.5 days. The mixture was filtered and diluted with EtOAc (100 mL). The solution was washed with saturated aqueous NaHCO3, brine, dried (MgSO4), and concentrated to give a brown foam. Purification by flash chromatography (eluent 5% MeOH/CHCl3) gave 4.5g of a white foam. Saturated methanolic HCl (45 mL) was added and the solution was concentrated to give a white foam. The foam was taken up in EtOH and boiled until a precipitate formed. Recrystallization from EtOH/H2O gave 1.75g (30%) of a white. solid m.p. 208- 210°C. NMR (DMSO-d6, 400 MHz): δ 2.98 (s, 3H), 3.04 (s, 3H), 3.55 (brs, 2H), 3.89 (brs,
3H), 3.96 (s, 3H), 4.60 (brs, 2H), 4.82 (brs, 2H), 7.23 (d, J = 8.5, 2H), 7.44 (m,
4H), 7.73 (d, J = 7.9, 1H), 7.76 (d, J = 8.0, 1H), 10.10 (s, 1H) IR (KBr, cm-1): 3440(NH), 1625 (C=0)
MS (m/e): 430 (MH+)
Anal. Calcd. for C21H29CI2N5O3S: C, 50.20; H, 5.82; N, 13.94%
Found: C, 50.13; H, 5.84; N, 13.72%. EXAMPLE 11
N-Methyl-N-[3-[methyl(1 -methyl-1H-benzimidazol-2-yl)- amino]pronyl]-4-[(methylsulfonyl)amino]benzenesulfonamide
Hydrochloride Step 1) Preparation of 2-[N-Methyl-N-[(2-methylamino)propyl)amino]-1-methyl-1H- benzimidazole
A mixture of 2-chloro-1-methylbenzimidazole (2.72 g, 16.4 mmol), N,N'-dimethyl-1,3- propanediamine (10.05 g, 98.4 mmol), and nBuOH (100 mL) was heated under reflux for 20 hours. The mixture was concentrated, taken up in H2O, and made basic (pH 9- 10) with 2.5 N NaOH.The mixture was extracted with EtOAc, and the combined extracts were dried and concentrated. Purification by flash chromatography (eluent Et3N/MeOH/CH2Cl2, 1:10:84) gave 3.37g (89%) of an orange oil. NMR (DMSO-d6, 300 MHz): δ 1.85 (m, 2H), 2.39 (s, 3H), 2.72 (t, J=6.1, 2H), 2.97 (s, 3H), 3.38 (t, J=6.2, 2H), 3.61 (s, 3H), 7.07 (m,2H), 7.32 (m, 2H).
Step 2) Preparation of N-Methyl-N-[3-[methyl(1-methyl-1H-benzimidazol-2- yl)amino]propyl]-4-[(memylsulfonyl)amino]benzenesulfonamide
Hydrochloride
To a stirred mixture of 2-[N-methyl-N-[(2-methylamino)propyl]amino]-1-methyl-1H- benzimidazole (1.61 g, 6.93 mmol), Et3N (0.70 g, 6.93 mmol), and dioxane (30 mL) was added 4-(methylsulfonyl)aminobenzenesulfonyl chloride (1.87 g, 6.93 mmol). After 1 hour, the mixture was concentrated, taken up in H2O, and extracted with EtOAc. The extracts were washed with H2O and brine, dried, and concentrated to give an off-white solid. Warm saturated methanolic HCl (30 mL) was added and the resulting white solid was collected by filtration to give 1.25 g (36%) of product m.p.233-234°C. NMR (DMSO-d6, 400 MHz): δ 1.91 (m, 2H), 2.64 (s, 3H), 2.98 (t, J=6.6 Hz, 2H), 3.11 (s, 3H), 3.27 (s, 3H), 3.59 (t, J=6.9 Hz, 2H), 3.79 (s, 3H), 7.35 (m, 4H), 7.47 (dd, J=4.8 Hz, 1.8 Hz, 1H), 7.60 (dd, J=4.8 Hz, 1.8 Hz, 1H), 7.69 (m, 2H), 10.50 (s, 1H); 13.65 (s, 1H)
IR (KBr, cm-1): 3400 (NH)
MS (m/e): 466 (MH+)
Anal. Calcd. for C20H28CIN5O4S2: C, 47.85; H, 5.62; N, 13.95%
Found: C, 47.92; H, 5.54; N, 13.87%.
EXAMPLE 12
N-[4-[[4-(1 -Methyl-1H-henzimidazol-2-y l)-1-piperazinyl]- sulfonyl]phenyl]m ethanesulfonamide Hydrochloride
Step 1) Preparation of 2-N-(1-Piperazinyl)-1-methyl-1H-benzimidazole
A mixture of 2-chloro-1-methylbenzimidazole (3.50 g, 0.021 mol), piperazine (10.86 g, 0.126 mol), and n-BuOH (100 mL) was heated under reflux for 24 hours. The mixture was concentrated, taken up in H2O, and made basic (pH 9-10) with 2.5 N NaOH. The aqueous mixture was extracted with EtOAc, and the extracts were dried and concentrated. Purification by flash chromatography (eluent 10% MeOH/CH2Cl2) gave 3.63g (80%) of a yellow solid m.p. 95-96°C. NMR (DMSO-d6, 300 MHz): δ 2.96 (m, 4H), 3.17 (m, 4H), 3.60 (s, 3H), 4.10 (s, 1H), 7.10 (m, 3H), 7.40 (dd, J = 3.9 Hz, 1.4 Hz, 1H).
Step 2) Preparation of N-[4-[[4-(1-Methyl-1H-benzimidazol-2-yl)piperazinyl]sulfonyl]- phenyl]methanesulfonamide Hydrochloride
To a stirred solution of 2-N-(1-piperazinyl)-1-methyl-1H-benzimidazole (4.09 g, 18.91 mmol) and Et3N (2.10 g, 20.80 mmol) in p-dioxane (100 mL) was added 4- (methylsulfonyl)aminobenzenesulfonyl chloride (5.10 g, 18.91 mmol). After 1 hour, the mixture was concentrated, suspended in H2O, and filtered. The resulting solid was triturated with EtOH. Saturated methanolic HCl (20 mL) was added and the solid was collected by filtration. Recrystallization from EtOH/H2O (3:1) gave 4.51g of an off- white solid.
NMR (DMSO-d6, 400 MHz): δ 3.13 (s, 4H), 3.14 (s, 3H), 3.65 (s, 4H), 3.66 (s, 3H), 7.32 (m, 1H), 7.36 (m, 1H), 7.40 (m, 2H), 7.49 (dd, J = 4.4 Hz, 1.8 Hz, 1H), 7.60 (dd, J = 4.4 Hz, 2.3 Hz, 1H), 7.74 (m, 2H), 10.60 (s, 1H) IR(KBr, cm-1: 3400 (NH)
MS (m/e): 450 (MH+)
Anal. Calcd. for C19H24CIN5O4S2: C, 46.96; H, 4.98; N, 14.41%
Found: C, 46.77; H, 4.91; N, 14.21%.
EXAMPLE 13
N-Methyl-N-[2-[methyl(1-methyl-1H-benzimidazol-2- yl) methyl]amino]ethyl-4-[(methylsulfonyl)amino]benzenesulfonamide
Dihydrochloride
To a stirred solution of 2-[[N-methyl-N-[(2-methylamino)ethyl]amino]methyl]-1-methyl- lH-benzimidazole (2.55g, 0.0110 mol) and Et3N(1.53 mL, 0.0110 mol) in CH2Cl2 (50 mL) was added 4-[(methylsulfonyl)amino]benzenesulfonyl chloride (2.96g, 0.0110 mol). After 4 hours, the mixture was diluted to 150 mL with CH2CI2, washed with saturated aqueous NaHCO3, dried (MgSO4), and concentrated to give an off-white foam. Purification by flash chromatography (eluent 5% MeOH/CHCl3) gave 4.9g of a white foam. Saturated methanolic HCl (50 mL) was added and the solution was concentrated to give an off-white foam. The foam was stirred in boiling EtOH until a precipitate formed. Recrystallization from EtOH/H2O (twice) gave 2.46g (42%) of a white solid m.p. 157-160°C.
NMR (DMSO-d6, 400 MHz): δ 2.70 (s, 3H), 2.89 (s, 3H), 3.13 (s, 3H), 3.36 (m, 2H), 3.43 (m, 2H), 3.94 (s, 3H), 4.71 (s, 2H), 7.39 (m, 4H), 7.75 (m, 4H), 10.57 (s, 1H)
IR (KBr, cm-1): 3400 (NH), 1590 (C = N)
MS (m/e): 466 (MH+)
Anal. Calcd. for C20H29Cl2N5O4S2: C, 44.61; H, 5.43; N, 13.00%
Found: C, 44.27; H, 5.81; N, 12.79%.
EXAMPLE 14
N-Methyl-N-[2-[ methyl(quinolin-2- yl)amino]ethyl]-4- [(methyls ulfonyl)amino]benzenes ulfonamide Hydrochloride
Step 1) Preparation of 2-[N-Methyl-N-[(2-methylamino)ethyl]amino]quinoline
A solution of 2-chloroquinoline (5.00g, 0.0306 mol) in N,N'-dimethylethylenediamine (25 mL, 0.235 mol) was heated under reflux for 20 hours, cooled, and concentrated. 10% aqueous HOAc (100 mL) was added and the mixture was filtered. The filtrate was extracted with EtOAc, and the aqueous phase was made basic (pH9) with solid KOH. The mixture was saturated wih NaCl and extracted with EtOAc. The combined extracts were dried (MgSO4) and concentrated to give 6.0g (91%) of a yellow oil.
NMR (DMSO-d6, 300 MHz): δ 2.30 (s, 3H), 2.69 (t, J = 6.7, 2H), 3.15 (s, 3H), 3.67 (t, J = 6.7, 2H), 7.06 (d, J = 9.2, 1H), 7.15 (m, 1H), 7.50 (M, 2H), 7.65
(dd, J = 7.6, 1.0, 1H), 7.97 (d, J = 9.2, 1H).
Step 2) Preparation of N-Methyl-N-[2-[methyl(quinolin-2-yl)amino]ethyl]-4-[(methyl- sulfonyl)amino]benzenesulfonamide Hydrochloride
To a stirred solution of 2-[N-methyl-N-[(2-methylamino)ethyl]amino]quinoline (3.00g, 0.0139 mol) and Et3N (1.94 mL, 0.0139 mol) in CH2CI2 (350 mL) was added 4- [(methylsulfonyl)amino]benzenesulfonyl chloride (3.76g, 0.0139 mol). After 20 hours, the mixture was washed with brine, dried (MgSO4), and concentrated. Purification by flash chromatography (eluent 5% MeOH/CH2Cl2) gave 5.5g of a white foam. Saturated methanolic HCl (70 mL) was added. The mixture was concentrated, triturated with hot MeOH, and dried to give 5.01g (74%) of a white solid m.ρ. 268-269°C. NMR (DMSO-d6, 400 MHz): δ 2.77 (s, 3H), 3.11 (s, 3H), 3.27 (m, 2H), 3.39 (s, 3H), 3.44 (m, 2H), 4.06 (brs, 1H), 7.33 (d, J = 8.7, 2H), 7.51 (m, 2H), 7.67 (d, J = 8.7, 2H), 7.79 (m, 1H), 7.94 (m, 1H), 8.43 (m, 1H)
IR (KBr, cm-1): 3400 (NH), 1640 (C = N)
MS (m/e): 449 (MH+)
Anal. Calcd. for C20H25CIN4O4S2: C, 49.53; H, 5.20; N, 11.55%
Found: C, 49.36; H, 5.02; N, 11.59%.
EXAMPLE 15
N-[4-(1-MethyI-1H-benzi midazol-2-yl)-1 -piperazinyl]-4- [(methylsnlfonyl)aminolbenzamide Hydrochloride Hemihydrate
A mixture of 2-N-(1-piperazinyl)-1-methyl-1H-benzimidazole (2.20 g, 10.17 mmol), 4- (methylsulfonyl)aminobenzoic acid (2.19 g, 10.17 mmol), 1-hydroxybenztriazole hydrate (1.37 g, 30.52 mmol), dicyclohexylcarbodiimide (1.95 g, 10.17 mmol), DMF (30 mL), and THF (50 mL) was stirred at room temperature for 2 days. The mixture was filtered and the filtrate was concentrated, taken up in H2O, and extracted with EtOAc. The combined extracts were washed with H2O, saturated aqueous NaHCθ3, brine, dried, and concentrated. Trituration with EtOH gave an off-white solid. The HCl salt was made with saturated methanolic HCl and was recrystallized from EtOH/H2O (3: 1) to give 1.95g (38%) of a white solid m.p. 225-256°C. NMR (DMSO-d6, 400 MHz): δ 3.06 (s, 3H), 3.89 (brs, 4H), 3.68 (s, 4H), 3.75 (s, 3H), 7.28 (m, 1H), 7.30 (m, 1H), 7.37 (m, 2H), 7.47 (m, 2H), 7.54 (m, 1H), 7.64 (dd, J = 7.5 Hz, 2.3 Hz, 1H), 10.12 (s, 1H)
IR (KBr, cm-1): 3600-3200 (NH), 1625 (CO)
MS (m/e): 414 (MH+)
Anal. Calcd. for C20H24CIN5O3S• 0.5 H2O: C, 52.34; H, 5.49; N, 15.26%
Found: C, 52.20; H, 5.17; N, 15.36%.
EXAMPLE 16
N-Methyl-N-[2-rmethyl[5-[(methylsulfonyl)a minol-1H-henzimidazol-2- yl]a mino]ethyl]benzamide
Step 1) Preparation of 2-Hydroxy-5-nitro-1H-benzimidazole
According to the procedure of A. T. James, et al., J. Chem. Soc, 1515, (1950), to cooled (0°C), stirred nitric acid (300 mL) was added all at once 2-hydroxy-1H- benzimidazole. After 1 minute a yellow precipitate had formed. The cooling bath was removed and stirring was continued for 10 minutes. The mixture was poured onto ice, and the off-white solid was collected by filtration and dried under vacuum at 60° C to give 25.1 g (94%) of product m.p. >300°C.
NMR (DMSO-d6, 300 MHz): δ 7.09 (d, J = 8.6, 1H), 7.70 (d, J = 2.3, 1H), 7.93 (dd, J = 8.6, 2.3, 1H), 11.17 (s, 1H), 11.40 (s, 1H).
Step 2) Preparation of 2-Chloro-5-nitro-1H-benzimidazole
According to the procedure of A.T. James, et al., J. Chem. Soc, 1515 (1950), a mixture of 2-hydroxy-5-nitro-1H-benzimidazole (10.0 g, 0.0558 mol) and phosphoryl chloride (100 mL) was heated under reflux for 3 hours. The mixture was cooled, concentrated, and ice water was added. The resulting precipitate was collected by filtration. NMR analysis showed the material to be a 1 : 1 mixture of starting material and product. (Note: Longer heating does not improve the conversion.) Purification by flash chromatography (material preadsorbed onto silica; eluent 40% EtOAc/hexane) gave 4.4g (40%) of the off-white solid product m.p. 215-217°C. NMR (DMSO-d6, 300 MHz): δ 7.68 (d, J = 8.9, 1H), 8.12 (dd, J = 8.9, 2.3, 1H), 8.39 (d, J = 2.3, 1H), 14.00 (brs, 1H).
Step 3) Preparation of 2-[N-Methyl-N-[(2-methylamino)ethyl]amino]-5-nitro-1H- benzimidazole
A solution of 2-chloro-5-nitro-1H-benzimidazole (7.5g, 0.038 mol) in N,N'-dimethyl- ethylenediamine (30.1 mL, 0.284 mol) was heated under reflux for 5 hours. The mixture was concentrated, taken up in 10% aqueous HOAc (200 mL) and extracted with EtOAc. The aqueous phase was filtered and made basic (pH8) with solid NaOH. The resulting orange solid 9.1g (96%) collected by filtration had m.p. 112-114°C.
NMR (DMSO-d6, 300 MHz): δ 2.31 (s, 3H), 2.73 (t, J = 6.3, 2H), 3.13 (s, 3H), 3.57 (t, J = 6.3, 2H), 7.22 (dd, J = 8.5, 0.4, 1H), 7.87 (m, 2H).
Step 4) Preparation of N-Methyl-N-[2-[methyl(5-nitro-1H-benzimidazol-2-yl)amino]- ethyl]benzamide
To a stirred solution of 2-[N-methyl-N-[(2-methylamino)ethyl]amino]-5-nitro-1H- benzimidazole (1.00 g, 4.01 mmol) and Et3N (0.426 g, 4.21 mmol) in THF (20 mL) was added benzoyl chloride (0.592 g, 4.21 mmol). After 1 hour, the mixture was diluted with EtOAc, washed with brine, saturated aqueous NaHCO3, brine, dried (MgSO4) and concentrated to give 1.3g (92%) of a yellow solid. NMR (DMSO-d6, 300 MHz): δ 2.95 and 3.05 (s, 3H),3.19 and 3.30 (s, 3H), 3.55, 3.65, 3.75, and 3.85 (s, 4H), 7.00-7.30 (m,-6H),-7.80 (m, 2H).
Note: The compound exists as a mixture of amide rotamers. The NMR peaks for both rotamers are listed above. Step 5) Preparation of N-Methyl-N-[2-[methyl(5-amino-1H-benzimidazbl-2-yl)- amino] ethyl] benzamide
A mixture of N-methyl-N-[2-[methyl(5-nitro- 1H-benzimidazol-2- yl)amino]ethyl]benzamide (1.30g, 3.68 mmol) and SnCl2• 2H2O (4.15g, 18.39 mmol) in EtOH (15 mL) was heated under reflux for 1 hour. The mixture was cooled and made basic (pH8) with 2.5N NaOH. The precipitate was removed by filtration and the filtrate was concentrated. The residue was stirred with EtOAc (150 mL) overnight, dried (MgSO4), and concentrated to give 1.12g-(94%) of a green foam. NMR (DMSO-d6, 300 MHz): δ 2.70 - 3.10 (m, 6H), 3.30 - 3.70 (m, 4H), 6.20 (m, 1H), 6.42 (m, 1H), 6.80 (m, 1H), 7.20 (m, 5H).
Note: The compound exists as a mixture of amide rotamers. Step 6) Preparation of N-Methyl-N-[2-[methyl[5-[(methylsulfonyl)amino]-1H- benzimidazol- 2-yl]amino]ethyl]benzamide
To a cooled (0°C) stirred solution of N-methyl-N-[2-[methyl(5-amino-lH-benzimidazol- 2-yl)amino]ethyl]benzamide (1.10 g, 3.40 mmol) and Et3N (0.50 mL, 3.57 mmol) in THF (20 mL) was added MsCl (0.41 g, 3.57 mmol). The cooling bath was removed and stirring was continued for 1.5 hours. Brine was added and the mixture was extracted with EtOAc. The extracts were dried (MgSO4) and concentrated to give a green foam. Purification by flash chromatography (eluent 5% MeOH/CHCl3; 10% MeOH/CHCl3) and again (eluent 7.5% MeOH/CHCl3) gave 863 mg of a green foam. Saturated methanolic HCl (10 mL) was added and the solution was concentrated to give a yellow foam. The foam was heated in EtOH/iPrOH (1 mL/10 mL) to give 400 mg (27%) of an off-white solid m.p. 264-265°C (dec).
NMR (DMSO-d6, 400 MHz): δ 2.91, 2.97, 3.00 and 3.05 (s, 6H), 3.25 (s, 3H), 3.58, 3.69, 3.77, and 3.92 (brs, 4H), 7.00 - 7.40 (m, 8H), 9.75 (s, 1H), 13.20 (brs, 1H). Note: The compound exists as a mixture of amide rotamers.
IR (KBr, cm-1): 3400, 3200 (NH), 1650 (C=0)
MS (m/e): 402 (MH+)
Anal. Calcd. for C19H24CIN5O3S: C, 52.11; H, 5.52; N, 15.99%
Found: C, 52.20; H, 5.50; N, 15.60%.
EXAMPLE 17
N-Methyl-N-[2-(2-methylamino-1H-benzimidazol-1-yl)ethyl]-4- [(methylsulfonyl)amino]benzenesulfona mide Hydrochloride
Step 1) Preparation of 2-(2-Nitroanilino)ethanol
According to the procedure of B. Agai, et al., Tetrahedron , 3 2, 839, (1976), a solution of 1-chloro-2-nitrobenzene (50.0 g, 0.317 mol) and 2-aminoethanol (116.3 g, 1.904 mol) in nBuOH (400 mL) was heated under reflux for 6 hours. The mixture was concentrated, taken up in H2O, and extracted with ether. The organic phase was washed with brine, dried, and concentrated to give 43.1g (75%) of an orange solid m.p. 78°C. NMR (DMSO-d6, 300 MHz): δ 3.40 (t, J = 5.4 Hz, 2H), 3.65 (t, J = 5.4 Hz, 2H), 4.98 (s, 1H), 6.70 (dd, J = 6.5 Hz, 2.2 Hz, 1H), 7.08 (m, 1H), 7.55 (m, 1H), 8.10 (dd, J = 7.2 Hz, 2.5 Hz, 1H), 8.21 (s, 1H). Step 2) Preparation of 2-(2-Aminoanilino)ethanol
According to the procedure of B. Agai, et al., Tetrahedron, 32, 839, (1976), a mixture of 2-(2-nitroanilino)ethanol (43.1 g, 0.237 mol), SnCl2• 2 H2O (267.0 g, 1.18 mol), and EtOH (400 mL), was heated under reflux for 4 hours. The mixture was cooled, made basic (pH8) with 2.5 N NaOH, and filtered through Celite. The filtrate was concentrated to remove the EtOH and the aqueous phase was extracted with EtOAc. The combined extracts were washed with H2O and brine, dried, and concentrated. Recrystallization from EtOH gave 31.0g (86%) of a brown solid m.p. 105- 106°C. NMR (DMSO-d6, 300 MHz): δ 3.10 (t, J = 5.6 Hz, 2H), 3.61 (s, 2H), 4.42 (s, 2H), 4.70 (t, J = 5.6 Hz, 2H), 6.40-6.60 (m, 4H).
Step 3) Preparation of 1-(2-Hydroxyethyl)-2-methylamino-1H-benzimidazole According to the procedure of B. Agai, et al., Tetrahedron, 32, 839, (1976), to a cooled (0°C), stirred suspension of 2-(2-aminoanilino)ethanol (30.4 g, 0.200 mol) in MeOH (100 mL) was added a solution of CH3NCS (14.6 g, 0.200 mol) in MeOH (60 mL) dropwise. The resulting mixture was stirred at room temperature for 4 hours and then heated under reflux for 15 minutes. CH3I (28.4 g, 0.200 mol) was added and the mixture was heated under reflux for 10 minutes, cooled to room temperature and stirred for 2 hours. Ether (200 mL) was added and the resulting precipitate was collected by filtration, taken up in nBuOH (140 mL), and heated under reflux for 10 hours. The mixture was cooled in the freezer for 3 hours and the white crystals were filtered. The material was dissolved in H2O and the solution was neutralized with 10% aqueous K2CO3. The white solid was collected by filtration to give 8.2 g (21%) of product m.p. >200°C.
NMR(DMSO-d6, 300 MHz): δ 2.89 (d, J=4.7 Hz, 3H), 3.65 (m, 2H), 3.99 (t, J=5.5 Hz, 2H), 4.97 (t, J=5.6 Hz, 1H), 6.43 (q, J=4.7 Hz, 1H), 6.90 (m, 2H), 7.15 (m, 2H).
Step 4) Preparation of 2-[2-Methylamino(benzimidazol-1-yl)]ethyl Methanesulfonate
To a cooled (0°C), stirred mixture of 1-(2-hydroxyethyl)-2-methylamino-1H- benzimidazole (8.05 g, 42.12 mmol), Et3N (4.26 g, 42.12 mmol), and CH2CI2 (85 mL) was added a solution of MsCl (4.83 g, 42.12 mmol) in CH2CI2 (10 mL). After 2 hours,
H2O was added and the layers were separated. The aqueous phase was extracted with CH2CI2. The combined extracts were washed with brine, dried, and concentrated to give 8.00g (71%) of a white solid m.p. 48-50°C.
NMR (DMSO-d6, 300 MHz): δ 2.95 (d, J = 4.7 Hz, 3H), 3.00 (s, 3H), 4.32(t, J = 5.5 Hz, 2H), 5.41 (t, J = 5.5 Hz, 2H), 6.70 (q, J = 4.7 Hz, 1H), 6.95 (m, 2H), 7.10 (m, 2H).
Step 5) Preparation of 1-[(2-Methylamino)ethyl]-2-memylamino-1H-benzimidazole A solution of 2-[2-methylamino(benzimidazol-1-yl)]ethyl methanesulfonate (8.0g, 29.7 mmol) and 33% CH3NH2/EtOH (60 mL) in EtOH (40 mL) was stirred at room temperature for 4 days. The mixture was concentrated, made basic (pH10) with 2.5 N NaOH, and extracted with EtOAc. The combined extracts were dried and concentrated to give a colorless oil. Purification by flash chromatography (eluent Et3N/MeOH/CH2Cl2, 1:10:84) gave 4.20g (70%) of an oil.
NMR (DMSO-d6, 300 MHz): δ 2.32 (s, 3H), 2.75 (t, J=5.5 Hz, 2H), 2.93 (s, 3H), 3.37 (s, 1H), 3.98 (t, J=5.5 Hz, 2H), 6.78 (s, 1H), 6.90 (m, 2H), 7.18 (m, 2H). Step 6) Preparation of N-Methyl-N-[2-(2-methylamino-1H-benzimidazol-1-yl)ethyl]-4- [(methylsulfonyl)a mino]benzenesulfonamide Hydrochloride
To a stirred solution of 1-[(2-methylamino)ethyl]-2-methylamino-1H-benzimidazole (2.00 g, 9.94 mmol) and Et3N (1.01 g, 9.94 mmol) in CH2CI2 (30 mL) was added 4- [(methylsulfonyl)aminojbenzenesulfonyl chloride (2.68 g, 9.94 mmol). After 1 hour, H2O was added and the resulting precipitate was collected by filtration. Warm methanolic HCl (50 mL) was added, the resulting solution was concentrated, and the solid was triturated with EtOH. Recrystallization from EtOH/H2O (4:1) gave 3.28g (70%) of a white solid m.p. 291-292°C.
NMR (DMSO-d6, 400 MHz): δ 2.76 (s, 3H), 3.05 (d, J=4.7 Hz, 3H), 3.11 (s, 3H), 3.29 (t, J = 5.5 Hz, 2H), 3.34 (s, 3H), 4.39 (t, J=5.5 Hz, 2H), 7.30 (m, 4H), 7.42 (dd, J=7.1 Hz, 0.9 Hz, 1H), 7.51 (m, 1H), 7.57 (m, 2H), 9.30 (s, 1H), 10.48 (s, 1H), 13.22 (s, 1H)
IR (KBr, cm-1): 3400 (NH), 1670 (C=N)
MS (m/e): 438 (MH+)
Anal. Calcd. for C18H24CIN5O4S2: C, 45.61; H, 5.10; N, 14.77%
Found: C, 45.62; H, 5.18; N, 14.87%. EXAMPLE 18
N-Methyl-N-[2-(2,3-dihydro-1 H-imidazo[1,2-albenzi midazol-1-yl)ethyl]- 4-[(methylsulfonyl)a minolhenzenesulfonamide Hydrochloride
Step 1) Preparation of 2-[N-bis(2-Hydroxyethyl)amino]-1H-benzimidazole
According to the procedure of V. A. Anisimova, et al., Khim. Farm. Zh., 22 (10), 1212, (1988), a solution of 2-chloro-1H-benzimidazole (5.00 g, 0.0328 mol) and diethanolamine (8.61 g, 0.0819 mol) in 3-methyl-1-butanol (75 mL) was heated under reflux for 44 hours. The mixture was cooled, concentrated, combined with material similarly derived from 1.00 g of starting material, and taken up in 10% aqueous HOAc (150 mL). The mixture was filtered and extracted with EtOAc. The aqueous phase was made basic (pH8) with solid KOH. The resulting white precipitate was collected by filtration to give 4.39 g (50%) of product m.p. 199-202°C. NMR (DMSO-d6, 300 MHz): δ 3.55 (m, 4H), 3.61 (m, 4H), 5.0 (brs, 2H), 6.84 (m, 2H), 7.11 (m , 2H).
Step 2) Preparation of 1-N-(2-Chloroethyl)-2,3-dihydro-1H-imidazo[1,2-a]- benzimidazole
According to the procedure of V. A. Anisimova, et al., Khim. Farm. Zh., 22 (10), 1212, (1988), to a stirred suspension of 2-[N-bis(2-hydroxyethyl)amino]-1H- benzimidazole (2.78 g, 12.56 mmol) in DMF (12 mL) was added thionyl chloride (5.08 g, 42.72 mmol). The mixture was heated under reflux for 1 hour, cooled, and poured onto ice (25 g). The mixture was made basic (pH9) with 2.5N NaOH and extracted with CHCI3. The extracts were dried (MgSO4) and concentrated to give a dark brown solid. Purification by flash chromatography (eluent CHCI3) gave 1.71g (62%) of a brown solid m.p. 110-112°C. NMR (DMSO-d6, 300 MHz): δ 3.64 (t, J = 6.2, 2H), 3.91 (t, J = 6.2, 2H), 4.01 (m, 2H), 4.14 (m, 2H), 6.94 (m, 2H), 7.13 (m, 1H), 7.20 (m, 1H).
Step 3) Preparation of 1-N-(2-Iodoethyl)-2,3-dihydro-1H-imidazo[1,2- a] benzimidazole
A mixture of Nal (1.73 g, 11.57 mmol) and 2-butanone (20 mL) was heated under reflux for 30 minutes 1-N-(2-Chloroethyl)-2,3-dihydro-1H-imidazo[1,2-a]benzimidazole (1.70 g, 7.71 mmol) and additional 2-butanone (5 mL) were added and heating was continued for 5 hours. EtOAc (50 mL) was added and the mixture was filtered. The filtrate was washed with H2O, 10% sodium bisulfite (25 mL), saturated aqueous NaHCO3, dried
(MgSO4) and concentrated to give 2.2g (92%) of a light brown solid m.p. 101-103°C.
NMR (DMSO - d6, 300 MHz): δ 3.50 (t, J = 6.3, 2H), 3.64 (t, J = 6.3, 2H), 3.98 (m, 2H), 4.14 (m, 2H), 6.94 (m, 2H), 7.13 (m, 1H), 7.21 (m, 1H).
Step 4) Preparation of [2-(2,3-dihydro-1H-imidazo-[1,2-a]benzimidazole-1- yl)ethyl]acetate
According to the procedure of N. Ono, et al., Bull. Chem. Soc. Jpn., 51 (8), 2401 (1978), a solution of 1-N-(2-iodoethyl)-2,3-dihydro-1H-imidazo[1,2-a]benzimidazole (2.20 g, 7.03 mmol), acetic acid (0.060 mL, 10.54 mmol) and DBU (1.57 mL, 10.54 mmol) in toluene (70 mL) was heated under reflux for 4 hours, cooled, and stirred at room temperature overnight. EtOAc (30 mL) was added and the mixture was washed with brine, dried (MgSO4), and concentrated to give 1.68g (98%) of a brown solid. This material was used without further purification in the next step (hydrolysis). NMR (DMSO - d6, 300 MHz): δ 2.00 (s, 3H), 3.55 (t, J = 5.4, 2H), 4.01 (m, 2H), 4.12 (m, 2H), 4.28 (t, J = 5.4, 2H), 6.93 (m, 2H), 7.12 (m, 1H), 7.20 (dd, J = 7.5, 1.8, 1H).
Step 5) Preparation of 1-N-(2-Hydroxyethyl)-2,3-dihydro-1H-imidazo[1,2-a]- benzimidazole
A solution of [2-(2,3-dihydro-1H-imidazo-[1,2-a]benzimidazol-1-yl)ethyl]acetate (1.67 g, 6.81 mmol) in 1 N NaOH (13.6 mL) and dioxane (10 mL) was stirred at room temperature for 1 hour, concentrated, suspended in H2O, and filtered to give 1.03g of a brown solid. Trituration with hot toluene (10 mL) gave 882 mg (64%) of an off-white solid m.p. 158-160°C.
NMR (DMSO - d6, 300 MHz): δ 3.35 (t, J = 5.7, 2H), 3.67 (t, J = 5.7, 2H), 3.99 (m, 2H), 4.10 (m, 2H), 4.95 (brs, 1H), 6.92 (m, 2H), 7.11 (dd, J = 6.7, 1.3, 1H), 7.17 (dd, J = 7.9, 2.0, 1H).
Step 6) Preparation of 1-N-[2-(Methylamino)ethyl]-2,3-dihydro-1H-imidazo[1,2-a]- benzimidazole
To a cooled (0°C), stirred suspension of 1-N-(2-hydroxyethyl)-2,3-dihydro-1H-imidazo- [1,2-a]benzimidazole (882 mg, 4.34 mmol) in CH2CI2 (18 mL) was added Et3N (0.67 mL, 4.77 mmol) and MsCl (0.37 mL, 4.77 mmol). The resulting solution was stirred at room temperature for 1 hour, washed with brine, dried (MgSO4) and concentrated to give an off-white solid. 33% CH3NH2/EtOH (45 mL) was added and the solution was stirred at room temperature over the weekend. The mixture was concentrated, taken up in 10% aqueous HOAc (20 mL) and extracted with EtOAc. The extracts were dried (MgSO4) and concentrated to give 738 mg (79%) of an off-white solid m.p. 60-63°C.
NMR (DMSO - d6, 300 MHz): δ 2.31 (s, 3H), 2.75 (t, J = 6.4, 2 H), 3.36 (t, J = 6.4, 2 H), 3.94 (m, 2H), 4.10 (m, 2H), 6.91 (m, 2H), 7.10 (dd, J = 6.9, 1.5, 1H), 7.17 (dd, J = 7.9, 2.1, 1H).
Step 7) Preparation of N-Methyl-N-[2-(2,3-dihydro-1H-imidazo[1,2-a]benzimidazol- 1 -yl)ethyl]-4-[(memylsu]fonyl)amino]benzenesulfonamide Hydrochloride
To a solution of 1 -N-[2-(methylamino)ethyl]-2,3-dihydro-1H-imidazo[1 ,2- a] benzimidazole (725 mg, 3.35 mmol) and Et3N (339 mg, 3.35 mmol) in CH2CI2 (50 mL) was added 4-[(methylsulfonyl)amino]benzenesulfonyl chloride (904 mg, 3.35 mmol). After 45 minutes, the solution was washed with brine, saturated aqueous NaHCO3, dried (MgSO4), and concentrated to 20 mL. The precipitate was collected by filtration to give 1.35 g of product m.p. 205-207°C. Saturated methanolic HCl (10mL) was added to a suspension of free base in MeOH (5 mL). The solution was concentrated to about 10 mL and left standing. The resulting white crystals were collected by filtration to give 1.31 g (80%) of product m.p. 215-217°C.
NMR (DMSO-d6, 400 MHz): δ 2.79 (s, 3H), 3.12 (s, 3H), 3.27 (t, J = 5.1, 2H), 3.77
(t, J = 5.1, 2H) 4.35 (m, 4H), 7.26 (m, 2H), 7.35 (d, J = 8.9, 2H), 7.41 (m, 2H), 7.73
(d, J = 8.9, 2H), 10.50 (s, 1H) IR (KBr, cm-1): 3400 (NH), 1675 (C=N)
MS (m/e): 450 (MH+)
Anal. Calcd. for C19H24CIN5O4S2: C, 46.96; H, 4.98; N, 14.41%
Found: C, 46.56; H, 4.91; N,14.19%. EXAMPLE 19
N-Methyl-N-[2-[methyl(quinolin-2-yl)aminolethyl-4-[methylsulfonyl)- aminolbenzamide
A mixture of 2-[N-methyl-N-[(2-methylamino)ethyl]amino]quinoline (3.00 g, 13.93 mmol), 1-hydroxybenztriazole hydrate (1.88 g, 13.93 mmol), dicyclohexylcarbodiimide (2.88 g, 13.93 mmol), 4-[(methylsulfonyl)amino]benzoic acid (3.00 g, 13.93 mmol), and THF (45 mL) was stirred at room temperature for 20 hours. The precipitate was removed by filtration and the filtrate was concentrated. The remaining material was taken up in CHCI3, and washed with saturated aqueous NaHCO3 and brine, dried, and concentrated. Purification by flash chromatography gave 2.1g of a white foam. The HCl salt was made, but could not be crystallized, and was reconverted to the free base. Recrystallization from iPrOH/EtOH and then EtOAc/EtOH gave 1.22g (21%) of a white solid m.p. 154-156°C.
Note: The compound exists as a mixture of amide rotamers.
The chemical shifts for both rotamers are listed.
NMR (DMSO - d6, 400 MHz): δ 2.84 and 2.94 (brs, 3H), 2.91 and 2.97 (brs, 3H), 3.06 and 3.17 (brs, 3H), 3.50 and 3.69 (brs, 2H), 3.78 and 3.94 (brs, 2H), 7.02 (m, 4H), 7.16 (m, 2H), 7.48 (m, 2H), 7.66 (m, 1H), 7.95 (m, 1H) 9.88 (s, 1H).
IR (KBr, cm-1): 1600 (C=O)
MS (m/e): 413 (MH+)
Anal. Calcd. for C21H24N4O3S: C, 61.15; H, 5.86; N, 13.58%
Found: C, 60.92; H, 5.98; N, 13.58%.

Claims

We claim:
1. The compounds of formula (I):
(I)
Figure imgf000045_0003
wherein R1 is H, NHSO2CH3 or 1-imidazolyl; Y is SO2 or C(O); n is 2 or 3; R2 and R3 are lower alkyl, containing 1 to 6 carbon atoms or, when n is 2, R2 and R3 are joined to form piperazine; R4 is selected from the group consisting of:
Figure imgf000045_0002
wherein R3 and R5 are lower alkyl containing 1 to 6 carbon atoms and Z is H or
NHSO2CH3; or R3 and R4 are joined to form
Figure imgf000045_0001
wherein Z is H or NHSO2CH3 or the pharmaceutically acceptable salt thereof.
2. The compounds according to claim 1 wherein R1 is H or NHSO2CH3; Y is SO2 or C(O); n is 2 or 3; R2 and R3 are lower alkyl containing 1 to 6 carbon atoms or, when n is 2, R2 and R3 are joined to form piperazine; R4 is selected from the group consisting of:
Figure imgf000046_0002
wherein R3 and R5 are lower alkyl containing 1 to 6 carbon atoms and Z is H or NHSO2CH3; or R3 and R4 are joined to form
Figure imgf000046_0001
wherein Z is H or NHSO2CH3 and the pharmaceutically accepted salts thereof.
3. The compound according to claim 2 N-methyl-N-[2-[methyl(1-methyl-1H-benzi midazol-2-yl)amino]ethyl-4-[(methylsulfonyl)amino]benzenesulfonamide and the pharmaceutically acceptable salts thereof.
4. The compound according to claim 1 4-[(methylsulfonyl)amino]-N-[2-(2- pyrimidinylamno)ethyl]benzenesulfonamide and the pharmaceutically acceptable salts thereof.
5. The compound according to claim 2 N-methyl-N-[2-[methyl(1-methyl-1H- benzimdazol-2-yl)amino]ethyl]-4-[(methylsulfonyl)amino]benzamide and the pharmaceutically acceptable salts thereof.
6. The compound according to claim 24-[(methylsulfonyl)amino]-N-[2-[(quinolin- 2-yl)amino]ethyl]benzenesulfonaιmde and the pharmaceutically acceptable salts thereof.
7. The compound according to claim 2 N-methyl-N-[2-[methyl(1-ethyl-1H- benzimidazol-2-yl)aιnino]ethyl]-4-[(methylsulfonyl)amino]benzenesulfonamide and the pharmaceutically acceptable salts thereof.
8. The compound according to claim 1 N-methyl-N-[2-[methyl[(1-methyl-1H- benzimidazol-2-yl)methyl]amino]ethyl]-4-[(methylsulfonyl)amino]benzamide and the pharmaceutically acceptable salts thereof.
9. The compound according to claim 1 N-methyl-N-[2-[methyl[(1-methyl-1H- benzi midazol-2-yl)methyl]ammo]ethyl]-4-[(methyϊsulfonyl)amino]benzenesulfonamide and the pharmaceutically acceptable salts thereof.
10. The compound according to claim 2 N-methyl-N-[2-[methyl(quinolin-2- yl)amino]ethyl]-4-[(memylsulfonyl)amino]benzenesulfonamide and the pharmaceutically acceptable salts thereof.
11. The compound according to claim 2 N-methyl-N-[2-[methyl[5- [(methylsulfonyl)amino]-1H-benzimidazol-2-yl]amino]ethyl]benzamide and the pharmaceutically acceptable salts thereof.
12. The compound according to claim 2 N-methyl-N-[2-(2,3-dihydro-1H- imidazo[1,2-a]benzimidazol-1-yl)ethyl]-4-[(methylsulfonyl)a mino]benzenesulfonamide and the pharmaceutically acceptable salts thereof.
13. The compound according to claim 2 N-methyl-N-[2-[methyl(quinolin-2- yl)amino]ethyl]-4-[(methylsulfonyl)amino]benzamide and the pharmaceutically acceptable salts thereof.
14. The compound according to claim 1 N-[2-[(1H-benzimidazol-2- ylmemyl)memylamino]ethyl]-N-methyl-4-[(methylsulfonyl)amino]benzenesulfonamide and the pharmaceutically acceptable salts thereof.
15. The compound according to claim 2 N-methyl-N-[3-[methyl(1-methyl-1H- benziιnidazol-2-yl)amino]propyl]-4-[(methylsulfonyl)amino]benzenesulfonamide and the pharmaceutically acceptable salts thereof.
16. The compound according to claim 2 N-methyl-N-[2-[methyl(1H-benzimidazol-2- yl)am ino]ethyl]-4-[(methylsulfonyl)amino]benzenesulfonamide and the pharmaceutically acceptable salts thereof.
17. The compound according to claim 2 N-[4-(1-methyl-1H-benzimidazol-2-yl)-1- piperazinyl]-4-[(methylsulfonyl)amino]benzamide and the pharmaceutically acceptable salts thereof.
18. The compound according to claim 2 N-[4-[[4-(1-methyl-1H-benzimidazol-2-yl)- 1-piperazinyl]sulfonyl]phenyl]methanesulfonamide and the pharmaceuticlaly acceptable salts thereof.
19. The compound according to claim 2 N-methyl-N-[2 -(2-methylamino)-1H- benzimidazol-1-yl)ethyl]-4-[(methylstιlfonyl)amino]benzenesulfonamide and the pharmaceutically acceptable salts thereof.
20. The compound according to claim 2 N-[2-[(1-methyl-1H-benzimidazol-2- yl)am ino]ethyl]-4-[(memylsu]fonyl)amino]benzenesulfonamide and the pharmaceutically acceptable salts thereof.
21. The compound according to claim 2 N-methyl-N-[2-[(1-methyl-1H-benzimidazol- 2-yl)amino]ethyl]-4-[(methylsulfonyl)amino]benzenesulfonamide and the pharmaceutically acceptable salts thereof.
22. The process for producing the compounds of formula (I)
(I)
Figure imgf000048_0001
wherein R1 is H, NHSO2CH3, NO2, or 1-imidazolyl; Y is SO2; n is 2 or 3; R2 and R3 are lower alkyl containing 1 to 6 carbon atoms or, when n is 2, R2 and R3 are joined to form piperazine; R4 is selected from the group consisting of:
Figure imgf000048_0002
wherein R3 and R5 are lower alkyl containing 1 to 6 carbon atoms and Z is H or
NHSO2CH3; or R3 and R4 are joined to form
Figure imgf000049_0004
wherein Z is H or NHSO2CH3 and die pharmaceutically acceptable salts thereof which comprises reacting the compound offormula
Figure imgf000049_0003
wherein R1 is as defined above with the compound of formula
.
Figure imgf000049_0002
wherein R2, R3, R4 and n are as defined above in the presence of a base and if desired converting said compound to a pharmaceutically acceptable salt.
23. The process of producing the compounds of formula (I) (01)
Figure imgf000049_0001
w0erein R1 is H, NHSO2CH3, NO2, or 1-imidazolyl; Y is C(O); n is 2 or 3; R2 and R3 are lower alkyl containing 1 to 6 carbon atoms or, when n is 2, R2 and R3 are joined to form piperazine; R4 is selected from the group consisting of:
Figure imgf000050_0003
wherein R3 and R5 are lower alkyl containing 1 to 6 carbon atoms and Z is H or
NHSO2CH3; or R3 and R4 are joined to form
Figure imgf000050_0004
wherein Z is H or NHSO2CH3 and the pharmaceutically acceptable salts thereof which comprises reacting the compound of formula -
Figure imgf000050_0001
wherein R1 is as defined above with the compound of formula
Figure imgf000050_0002
wherein R2, R3, R4 and n are as defined above in the presence of DCC and if desired converting said compound to a pharmaceutically acceptable salt.
24. The process for producing the compounds of formula (I)
/ (I)
Figure imgf000051_0004
wherein R1 is H, NHSO2CH3 NO2, or 1-imidazolyl; Y is C(O); n is 2 or 3; R2 and R3 are lower alkyl containing 1 to 6 carbon atoms or, when n is 2, R2 and R3 are joined to form piperazine; R4 is selected from the group consisting of:
Figure imgf000051_0001
wherein R3 and R5 are lower alkyl containing 1 to 6 carbon atoms and Z is H or
NHSO2CH3; or R3 and R4 are joined to form
Figure imgf000051_0002
wherein Z is H or NHSO2CH3 and the pharmaceutically acceptable salts thereof which comprises reacting the compound of formula
Figure imgf000051_0003
wherein R1 is as defined above with the compound of formula
Figure imgf000052_0001
H- N- (CH2)n- N- R4 2 wherein R2, R3, R4 and n are as defined above in the presence of a base and if desired converting said compound to a pharmaceutically acceptable salt.
25. A pharmaceutical composition having antiarrhythmic properties which comprises an effective amount of a compound of the formula (I) of claim 1 or its physiologically tolerated acid addition salt and a pharmaceutically acceptable carrier and/or diluent.
26. A method of treating arrhythmia which comprises administering an effective amount of a compound of die formula (I) of claim 1 or its pharmaceutically acceptable acid addition salt.
PCT/US1991/003793 1990-05-30 1991-05-29 Substituted arylsulfonamides and benzamides WO1991018904A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP91510857A JPH05507702A (en) 1990-05-30 1991-05-29 Substituted arylsulfonamides and benzamides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53068490A 1990-05-30 1990-05-30
US530,684 1990-05-30

Publications (1)

Publication Number Publication Date
WO1991018904A1 true WO1991018904A1 (en) 1991-12-12

Family

ID=24114566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/003793 WO1991018904A1 (en) 1990-05-30 1991-05-29 Substituted arylsulfonamides and benzamides

Country Status (3)

Country Link
JP (1) JPH05507702A (en)
AU (1) AU7997091A (en)
WO (1) WO1991018904A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0512939A1 (en) * 1991-05-10 1992-11-11 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) New 2-piperazinylbenzimidazole derivatives
EP0628549A1 (en) * 1993-05-21 1994-12-14 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) New 1-phenylmethyl benzimidazole piperazine derivatives
WO2003051872A1 (en) * 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. Ethylene diamine derivatives and their use as orexin-receptor antagonists
EP1528924A1 (en) * 2002-07-08 2005-05-11 Astrazeneca AB Mch1r antagonists
WO2005080348A1 (en) 2004-02-19 2005-09-01 Banyu Pharmaceutical Co., Ltd. Novel sulfone amide derivative
EP2194058A1 (en) 2002-09-04 2010-06-09 Schering Corporation Pyrazolopyrimidines suitable for the treatment of cancer diseases
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2652398A (en) * 1949-11-17 1953-09-15 Endo Products Inc N-substituted-2-amino (methyl) quinolines
US2971005A (en) * 1958-10-17 1961-02-07 Merck & Co Inc Nu-substituted derivatives of 2-benzylaminobenzimidazoles
EP0094498A2 (en) * 1982-05-06 1983-11-23 American Cyanamid Company Antiatherosclerotic 1-piperazine derivatives
US4544654A (en) * 1984-03-20 1985-10-01 Schering A.G. Substituted sulfonamidobenzamides, antiarrhythmic agents and compositions thereof
CH659069A5 (en) * 1983-11-02 1986-12-31 Sandoz Ag 2-Piperazino- or -homopiperazino-quinazoline derivatives, process for their preparation and pharmaceuticals containing them
US4721809A (en) * 1986-09-18 1988-01-26 American Home Products Corporation Alkylsulfonamido or perfluoroalkylsulfonamido benzenesulfonamides
EP0290377A1 (en) * 1987-05-05 1988-11-09 Schering Aktiengesellschaft Substituted 4-[1H-Imidazol-1-yl] benzamides as antiarrhythmic agents
EP0306440A2 (en) * 1987-09-04 1989-03-08 Schering Aktiengesellschaft 1-(4-substituted phenyl)-1H-imidazoles as cardiovascular agents
EP0330065A1 (en) * 1988-02-18 1989-08-30 Kowa Company, Ltd. Sulfonamide compounds
EP0358284A2 (en) * 1988-07-13 1990-03-14 Schering Aktiengesellschaft Derivatized alkanolamines as cardiovascular agents

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2652398A (en) * 1949-11-17 1953-09-15 Endo Products Inc N-substituted-2-amino (methyl) quinolines
US2971005A (en) * 1958-10-17 1961-02-07 Merck & Co Inc Nu-substituted derivatives of 2-benzylaminobenzimidazoles
EP0094498A2 (en) * 1982-05-06 1983-11-23 American Cyanamid Company Antiatherosclerotic 1-piperazine derivatives
CH659069A5 (en) * 1983-11-02 1986-12-31 Sandoz Ag 2-Piperazino- or -homopiperazino-quinazoline derivatives, process for their preparation and pharmaceuticals containing them
US4544654A (en) * 1984-03-20 1985-10-01 Schering A.G. Substituted sulfonamidobenzamides, antiarrhythmic agents and compositions thereof
US4721809A (en) * 1986-09-18 1988-01-26 American Home Products Corporation Alkylsulfonamido or perfluoroalkylsulfonamido benzenesulfonamides
US4721809B1 (en) * 1986-09-18 1989-06-06
EP0290377A1 (en) * 1987-05-05 1988-11-09 Schering Aktiengesellschaft Substituted 4-[1H-Imidazol-1-yl] benzamides as antiarrhythmic agents
EP0306440A2 (en) * 1987-09-04 1989-03-08 Schering Aktiengesellschaft 1-(4-substituted phenyl)-1H-imidazoles as cardiovascular agents
EP0330065A1 (en) * 1988-02-18 1989-08-30 Kowa Company, Ltd. Sulfonamide compounds
EP0358284A2 (en) * 1988-07-13 1990-03-14 Schering Aktiengesellschaft Derivatized alkanolamines as cardiovascular agents

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0512939A1 (en) * 1991-05-10 1992-11-11 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) New 2-piperazinylbenzimidazole derivatives
ES2038532A1 (en) * 1991-05-10 1993-07-16 Espanola Prod Quimicos New 2-piperazinylbenzimidazole derivatives.
EP0628549A1 (en) * 1993-05-21 1994-12-14 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) New 1-phenylmethyl benzimidazole piperazine derivatives
ES2072193A1 (en) * 1993-05-21 1995-07-01 Espanola Prod Quimicos New 1-phenylmethyl benzimidazole piperazine derivatives.
US5672604A (en) * 1993-05-21 1997-09-30 Fabrica Espanola De Productos Quimicos Y Farmaceuticos (Faes) 1-phenylmethyl benzimidazole piperazine derivative
WO2003051872A1 (en) * 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. Ethylene diamine derivatives and their use as orexin-receptor antagonists
US7468367B2 (en) 2001-12-19 2008-12-23 Smithkline Beecham P.L.C. Ethylene diamine derivatives and their use as orexin-receptor antagonists
EP1528924A1 (en) * 2002-07-08 2005-05-11 Astrazeneca AB Mch1r antagonists
EP2194058A1 (en) 2002-09-04 2010-06-09 Schering Corporation Pyrazolopyrimidines suitable for the treatment of cancer diseases
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
WO2005080348A1 (en) 2004-02-19 2005-09-01 Banyu Pharmaceutical Co., Ltd. Novel sulfone amide derivative

Also Published As

Publication number Publication date
AU7997091A (en) 1991-12-31
JPH05507702A (en) 1993-11-04

Similar Documents

Publication Publication Date Title
JP3645579B2 (en) Antiarrhythmic and cardioprotective substitution-1 (2H) isoquinolines, their preparation, medicaments containing them and their use to produce medicaments for treating cardiac dysfunction
US4788196A (en) Phenyl piperazine anti-arrhythmia agents
DE69927050T2 (en) BIPHENYL COMPOUNDS AND BIPHENYL ANALOGS AS INTERGRIN ANTAGONISTS
JP4323803B2 (en) Substituted 2-anilinobenzimidazoles and their use as NHE inhibitors
JP4023841B2 (en) Heterocyclyl-benzoylguanidine compounds
CS249544B2 (en) Method of new imidazolylphenylamidines production
WO1991018904A1 (en) Substituted arylsulfonamides and benzamides
US5149700A (en) Substituted arylsulfonamides and benzamides
CA2504213A1 (en) New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
EP1144381A2 (en) Substituted benzo[de]isoquinoline-1,3-diones
AU2003300297A1 (en) CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST Beta-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE
JPH04273878A (en) Heterocyclic compound and preparation thereof
PL172933B1 (en) Method of obtaining novel derivatives of 3/2h/-pyridazone
US5202346A (en) Piperidinyl and piperazinyl derivatives
US5576327A (en) Treatment of heart rhythym disorders by administration of 3-phenylsulfonyl-3, 7-diazabicyclo[3.3.1]nonane compounds
US4617393A (en) 5-substituted-6-aminopyrimidines, composition and uses as cardiotonic agents for increasing cardiac contractility
JPH0613506B2 (en) Antiarrhythmic agent
AU2020430369A1 (en) Thieno[2,3-d]pyrimidine HIV-1 non-nucleoside reverse transcriptase inhibitor, preparation method therefor and use thereof
US4994459A (en) Aryloxypropane substituted piperazine derivatives with antiarrhythmic and antifibrillatory activity
US5254689A (en) Piperdinyl and piperazinyl derivatives
JPH03181473A (en) Heterocyclic compound, its preparation, drug containing same for treating cardiovascular affection and intermediate for use in its preparation
NZ228871A (en) 6-oxo-pyridazine derivatives and pharmaceutical compositions
HU207511B (en) Process for producing pirimidinium derivatives, nonionic formes of them and pharmaceutical compositions containing them
US4882323A (en) 1,2,3,4,5,6-hexahydro[1,3,6]triazocino[1,1-a]benzimidazoles
US5104892A (en) Substituted benzimidazole derivatives possessing Class III antiarrhythmic activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA